EP0880503A1 - Balanol analogues - Google Patents
Balanol analoguesInfo
- Publication number
- EP0880503A1 EP0880503A1 EP97901527A EP97901527A EP0880503A1 EP 0880503 A1 EP0880503 A1 EP 0880503A1 EP 97901527 A EP97901527 A EP 97901527A EP 97901527 A EP97901527 A EP 97901527A EP 0880503 A1 EP0880503 A1 EP 0880503A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- optionally substituted
- designates
- optionally
- alkyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- XYUFCXJZFZPEJD-PGRDOPGGSA-N balanol Chemical class OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-PGRDOPGGSA-N 0.000 title description 24
- 238000000034 method Methods 0.000 claims abstract description 76
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- -1 sulphanyl Chemical group 0.000 claims description 105
- 150000001875 compounds Chemical class 0.000 claims description 93
- 125000001072 heteroaryl group Chemical group 0.000 claims description 50
- 125000000524 functional group Chemical group 0.000 claims description 39
- 230000015572 biosynthetic process Effects 0.000 claims description 36
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 239000007787 solid Substances 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- 125000003107 substituted aryl group Chemical group 0.000 claims description 25
- 238000005859 coupling reaction Methods 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 21
- 230000008878 coupling Effects 0.000 claims description 20
- 238000010168 coupling process Methods 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 238000010511 deprotection reaction Methods 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 18
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 17
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 238000012216 screening Methods 0.000 claims description 13
- 125000001246 bromo group Chemical group Br* 0.000 claims description 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 10
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 9
- 229930194542 Keto Natural products 0.000 claims description 9
- 125000000468 ketone group Chemical group 0.000 claims description 9
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 7
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 229910006069 SO3H Inorganic materials 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 abstract description 23
- 150000002148 esters Chemical class 0.000 abstract description 19
- VTAZRSXSBIHBMH-UHFFFAOYSA-N Ophiocordin Natural products OC1=CC(C(=O)O)=CC(O)=C1C(=O)C1=C(O)C=CC=C1C(=O)NC1C(OC(=O)C=2C=CC(O)=CC=2)CCCNC1 VTAZRSXSBIHBMH-UHFFFAOYSA-N 0.000 abstract description 11
- 102000003923 Protein Kinase C Human genes 0.000 abstract description 8
- 108090000315 Protein Kinase C Proteins 0.000 abstract description 8
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract description 7
- 150000008064 anhydrides Chemical class 0.000 abstract description 6
- 230000004048 modification Effects 0.000 abstract description 3
- 238000012986 modification Methods 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 abstract description 2
- 238000010916 retrosynthetic analysis Methods 0.000 abstract description 2
- XYUFCXJZFZPEJD-XMSQKQJNSA-N balanol Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-XMSQKQJNSA-N 0.000 abstract 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 abstract 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 abstract 2
- AAHDJEGSJGYRGS-IHYXAKMNSA-N (4z)-4-[(2-carboxy-6-hydroxyphenyl)-hydroxymethylidene]-3-hydroxy-1-[(3r,4r)-3-[(4-hydroxybenzoyl)amino]-2,3,4,5-tetrahydro-1h-azepin-4-yl]-5-oxocyclohex-2-ene-1-carboxylic acid Chemical compound OC(=O)C1=CC=CC(O)=C1\C(O)=C\1C(O)=CC(C(O)=O)([C@@H]2[C@H](CNC=CC2)NC(=O)C=2C=CC(O)=CC=2)CC/1=O AAHDJEGSJGYRGS-IHYXAKMNSA-N 0.000 abstract 1
- 229940000406 drug candidate Drugs 0.000 abstract 1
- 238000013537 high throughput screening Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 70
- 239000011347 resin Substances 0.000 description 34
- 229920005989 resin Polymers 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- 125000004122 cyclic group Chemical group 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 239000002253 acid Substances 0.000 description 14
- 238000003776 cleavage reaction Methods 0.000 description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 14
- 230000007017 scission Effects 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 8
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000003875 Wang resin Substances 0.000 description 8
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 8
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 8
- MDYOLVRUBBJPFM-UHFFFAOYSA-N tropolone Chemical compound OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 150000001299 aldehydes Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 150000001414 amino alcohols Chemical class 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 150000001601 aromatic carbocyclic compounds Chemical class 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 5
- RXOHFPCZGPKIRD-UHFFFAOYSA-N naphthalene-2,6-dicarboxylic acid Chemical compound C1=C(C(O)=O)C=CC2=CC(C(=O)O)=CC=C21 RXOHFPCZGPKIRD-UHFFFAOYSA-N 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 125000004043 oxo group Chemical group O=* 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 4
- SCEIUGQQBYRBPP-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-azepine Chemical compound C1CCC=CNC1 SCEIUGQQBYRBPP-UHFFFAOYSA-N 0.000 description 4
- BEWVAZNECYSPMT-UHFFFAOYSA-N 2,3-dihydro-1h-azepine Chemical compound C1CC=CC=CN1 BEWVAZNECYSPMT-UHFFFAOYSA-N 0.000 description 4
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 4
- GHDIYKFLTNEMAC-UHFFFAOYSA-N 2-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)(C=1C=CC=CC=1)OCC1=CC=CC=C1C(O)=O GHDIYKFLTNEMAC-UHFFFAOYSA-N 0.000 description 4
- BUBVLQDEIIUIQG-UHFFFAOYSA-N 3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-one Chemical compound C=1C=CC=CC=1COC1C(OCC=2C=CC=CC=2)C(OCC=2C=CC=CC=2)C(=O)OC1COCC1=CC=CC=C1 BUBVLQDEIIUIQG-UHFFFAOYSA-N 0.000 description 4
- MXNBDFWNYRNIBH-UHFFFAOYSA-N 3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1 MXNBDFWNYRNIBH-UHFFFAOYSA-N 0.000 description 4
- LFEWXDOYPCWFHR-UHFFFAOYSA-N 4-(4-carboxybenzoyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)C1=CC=C(C(O)=O)C=C1 LFEWXDOYPCWFHR-UHFFFAOYSA-N 0.000 description 4
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 4
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 4
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 4
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 4
- 150000002391 heterocyclic compounds Chemical class 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 3
- ZBTMRBYMKUEVEU-UHFFFAOYSA-N 1-bromo-4-methylbenzene Chemical compound CC1=CC=C(Br)C=C1 ZBTMRBYMKUEVEU-UHFFFAOYSA-N 0.000 description 3
- RWHRIIMYBNGFEV-UHFFFAOYSA-N 2-(4-carboxybenzoyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)C1=CC=CC=C1C(O)=O RWHRIIMYBNGFEV-UHFFFAOYSA-N 0.000 description 3
- JJVATGCCSPHKKV-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(1-hydroxybutan-2-yl)carbamate Chemical compound C1=CC=C2C(COC(=O)NC(CO)CC)C3=CC=CC=C3C2=C1 JJVATGCCSPHKKV-UHFFFAOYSA-N 0.000 description 3
- LXJRKFSWUZABMU-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(2-hydroxypropyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCC(O)C)C3=CC=CC=C3C2=C1 LXJRKFSWUZABMU-UHFFFAOYSA-N 0.000 description 3
- GNXZNUJDAMSJFZ-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(3-hydroxypropyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCO)C3=CC=CC=C3C2=C1 GNXZNUJDAMSJFZ-UHFFFAOYSA-N 0.000 description 3
- HHNJBGORPSTJDX-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-hydroxycarbamate Chemical class C1=CC=C2C(COC(=O)NO)C3=CC=CC=C3C2=C1 HHNJBGORPSTJDX-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- PBAYDYUZOSNJGU-UHFFFAOYSA-N Chelidonic acid Chemical compound OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 3
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- RGEVWUKXWFOAID-UHFFFAOYSA-N Piperidione Chemical compound CCC1(CC)C(=O)CCNC1=O RGEVWUKXWFOAID-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 229940111759 benzophenone-2 Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000007942 carboxylates Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- ASQQEOXYFGEFKQ-UHFFFAOYSA-N dioxirane Chemical compound C1OO1 ASQQEOXYFGEFKQ-UHFFFAOYSA-N 0.000 description 3
- GWZCCUDJHOGOSO-UHFFFAOYSA-N diphenic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CC=C1C(O)=O GWZCCUDJHOGOSO-UHFFFAOYSA-N 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000003667 hormone antagonist Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- KHARCSTZAGNHOT-UHFFFAOYSA-N naphthalene-2,3-dicarboxylic acid Chemical compound C1=CC=C2C=C(C(O)=O)C(C(=O)O)=CC2=C1 KHARCSTZAGNHOT-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 229960003810 piperidione Drugs 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000012286 potassium permanganate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical group 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- IKCBNUVGOJSNDB-UHFFFAOYSA-N (2-methylphenyl)-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=CC=C1C IKCBNUVGOJSNDB-UHFFFAOYSA-N 0.000 description 2
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical group [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 2
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 2
- LXQMHOKEXZETKB-UHFFFAOYSA-N 1-amino-2-methylpropan-2-ol Chemical compound CC(C)(O)CN LXQMHOKEXZETKB-UHFFFAOYSA-N 0.000 description 2
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 2
- WJIFKOVZNJTSGO-UHFFFAOYSA-N 1-bromo-3-methylbenzene Chemical compound CC1=CC=CC(Br)=C1 WJIFKOVZNJTSGO-UHFFFAOYSA-N 0.000 description 2
- HQCZLEAGIOIIMC-UHFFFAOYSA-N 1-methoxy-2-methyl-3-nitrobenzene Chemical compound COC1=CC=CC([N+]([O-])=O)=C1C HQCZLEAGIOIIMC-UHFFFAOYSA-N 0.000 description 2
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 2
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 2
- WKSIHEZXQNJQCB-UHFFFAOYSA-N 2-(4-carboxyphenyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1C(O)=O WKSIHEZXQNJQCB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- XCOUVPWGTSKINY-UHFFFAOYSA-N 2-methoxy-4-methyl-1-nitrobenzene Chemical compound COC1=CC(C)=CC=C1[N+]([O-])=O XCOUVPWGTSKINY-UHFFFAOYSA-N 0.000 description 2
- NWPNXBQSRGKSJB-UHFFFAOYSA-N 2-methylbenzonitrile Chemical compound CC1=CC=CC=C1C#N NWPNXBQSRGKSJB-UHFFFAOYSA-N 0.000 description 2
- OPXLVWLFDKRYRB-UHFFFAOYSA-N 3-methoxy-2-methylaniline Chemical compound COC1=CC=CC(N)=C1C OPXLVWLFDKRYRB-UHFFFAOYSA-N 0.000 description 2
- NEQFBGHQPUXOFH-UHFFFAOYSA-N 4-(4-carboxyphenyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C(O)=O)C=C1 NEQFBGHQPUXOFH-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- VCZNNAKNUVJVGX-UHFFFAOYSA-N 4-methylbenzonitrile Chemical compound CC1=CC=C(C#N)C=C1 VCZNNAKNUVJVGX-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- CFUJPPDHENSXIG-SHTZXODSSA-N C1C[C@@H](O)CC[C@@H]1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1C[C@@H](O)CC[C@@H]1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 CFUJPPDHENSXIG-SHTZXODSSA-N 0.000 description 2
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 2
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 108020005497 Nuclear hormone receptor Chemical group 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000464 adrenergic agent Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000002402 anti-lipaemic effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000003926 antimycobacterial agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 239000003699 antiulcer agent Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- FHRRJZZGSJXPRQ-UHFFFAOYSA-N benzyl phenylmethoxycarbonyl carbonate Chemical class C=1C=CC=CC=1COC(=O)OC(=O)OCC1=CC=CC=C1 FHRRJZZGSJXPRQ-UHFFFAOYSA-N 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000002371 cardiac agent Substances 0.000 description 2
- 239000003874 central nervous system depressant Substances 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 2
- 239000000064 cholinergic agonist Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- MUYSADWCWFFZKR-UHFFFAOYSA-N cinchomeronic acid Chemical compound OC(=O)C1=CC=NC=C1C(O)=O MUYSADWCWFFZKR-UHFFFAOYSA-N 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- OOXWYYGXTJLWHA-UHFFFAOYSA-N cyclopropene Chemical compound C1C=C1 OOXWYYGXTJLWHA-UHFFFAOYSA-N 0.000 description 2
- 238000007257 deesterification reaction Methods 0.000 description 2
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 2
- YRTMEEURRDTMST-UHFFFAOYSA-N diazetidine Chemical compound C1CNN1 YRTMEEURRDTMST-UHFFFAOYSA-N 0.000 description 2
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 description 2
- KJGHYQZXEYTDSW-UHFFFAOYSA-N diazocane Chemical compound C1CCCNNCC1 KJGHYQZXEYTDSW-UHFFFAOYSA-N 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 150000002085 enols Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- ZHQLTKAVLJKSKR-UHFFFAOYSA-N homophthalic acid Chemical compound OC(=O)CC1=CC=CC=C1C(O)=O ZHQLTKAVLJKSKR-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000005217 methyl ethers Chemical class 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- KYTZHLUVELPASH-UHFFFAOYSA-N naphthalene-1,2-dicarboxylic acid Chemical compound C1=CC=CC2=C(C(O)=O)C(C(=O)O)=CC=C21 KYTZHLUVELPASH-UHFFFAOYSA-N 0.000 description 2
- JSKSILUXAHIKNP-UHFFFAOYSA-N naphthalene-1,7-dicarboxylic acid Chemical compound C1=CC=C(C(O)=O)C2=CC(C(=O)O)=CC=C21 JSKSILUXAHIKNP-UHFFFAOYSA-N 0.000 description 2
- 208000018360 neuromuscular disease Diseases 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 description 2
- XHWNEBDUPVMPKI-UHFFFAOYSA-N oxazetidine Chemical compound C1CON1 XHWNEBDUPVMPKI-UHFFFAOYSA-N 0.000 description 2
- KKHNAVZYZJMXFV-UHFFFAOYSA-N oxazocane Chemical compound C1CCCONCC1 KKHNAVZYZJMXFV-UHFFFAOYSA-N 0.000 description 2
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 2
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 2
- HZIVRQOIUMAXID-UHFFFAOYSA-N oxocane Chemical compound C1CCCOCCC1 HZIVRQOIUMAXID-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000001725 pyrenyl group Chemical group 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 150000003335 secondary amines Chemical group 0.000 description 2
- 230000004799 sedative–hypnotic effect Effects 0.000 description 2
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 150000008143 steroidal glycosides Chemical class 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- HQHCYKULIHKCEB-UHFFFAOYSA-N tetradecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCC(O)=O HQHCYKULIHKCEB-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 2
- PGAZQSBUJDVGIX-UHFFFAOYSA-N thiazepane Chemical compound C1CCNSCC1 PGAZQSBUJDVGIX-UHFFFAOYSA-N 0.000 description 2
- VZYZKDFMQQEERI-UHFFFAOYSA-N thiazocane Chemical compound C1CCCSNCC1 VZYZKDFMQQEERI-UHFFFAOYSA-N 0.000 description 2
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 2
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 2
- AMIGYDGSJCJWSD-UHFFFAOYSA-N thiocane Chemical compound C1CCCSCCC1 AMIGYDGSJCJWSD-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 2
- 229930004006 tropane Natural products 0.000 description 2
- LWBHHRRTOZQPDM-UHFFFAOYSA-N undecanedioic acid Chemical compound OC(=O)CCCCCCCCCC(O)=O LWBHHRRTOZQPDM-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- WXKBWWIWJCCING-QWWZWVQMSA-N (1r,2r)-2-aminocyclobutan-1-ol Chemical compound N[C@@H]1CC[C@H]1O WXKBWWIWJCCING-QWWZWVQMSA-N 0.000 description 1
- ZWOFTVSNNFYPAB-RNFRBKRXSA-N (1r,2r)-2-aminocycloheptan-1-ol Chemical compound N[C@@H]1CCCCC[C@H]1O ZWOFTVSNNFYPAB-RNFRBKRXSA-N 0.000 description 1
- PQMCFTMVQORYJC-PHDIDXHHSA-N (1r,2r)-2-aminocyclohexan-1-ol Chemical compound N[C@@H]1CCCC[C@H]1O PQMCFTMVQORYJC-PHDIDXHHSA-N 0.000 description 1
- DUJAFYDYPPBLOY-HTQZYQBOSA-N (1r,2r)-2-aminocyclooctan-1-ol Chemical compound N[C@@H]1CCCCCC[C@H]1O DUJAFYDYPPBLOY-HTQZYQBOSA-N 0.000 description 1
- JFFOUICIRBXFRC-RFZPGFLSSA-N (1r,2r)-2-aminocyclopentan-1-ol Chemical compound N[C@@H]1CCC[C@H]1O JFFOUICIRBXFRC-RFZPGFLSSA-N 0.000 description 1
- ILUAAIDVFMVTAU-OLQVQODUSA-N (1s,2r)-cyclohex-4-ene-1,2-dicarboxylic acid Chemical compound OC(=O)[C@H]1CC=CC[C@H]1C(O)=O ILUAAIDVFMVTAU-OLQVQODUSA-N 0.000 description 1
- GXKNWUBHRTXZMI-UHFFFAOYSA-N (2-methoxy-5-methylphenyl)-(4-methylphenyl)methanone Chemical compound COC1=CC=C(C)C=C1C(=O)C1=CC=C(C)C=C1 GXKNWUBHRTXZMI-UHFFFAOYSA-N 0.000 description 1
- TXXHDPDFNKHHGW-UHFFFAOYSA-N (2E,4E)-2,4-hexadienedioic acid Natural products OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 1
- PSSWASGEGXCINO-RFZPGFLSSA-N (3R,4R)-3-aminopiperidin-4-ol Chemical compound N[C@@H]1CNCC[C@H]1O PSSWASGEGXCINO-RFZPGFLSSA-N 0.000 description 1
- ZZWNCDLYERZDIQ-PHDIDXHHSA-N (3r,4r)-3-aminoazepan-4-ol Chemical compound N[C@@H]1CNCCC[C@H]1O ZZWNCDLYERZDIQ-PHDIDXHHSA-N 0.000 description 1
- IRWCLYGRXRJJSF-PHDIDXHHSA-N (3r,4r)-4-aminoazepan-3-ol Chemical compound N[C@@H]1CCCNC[C@H]1O IRWCLYGRXRJJSF-PHDIDXHHSA-N 0.000 description 1
- UVBKPWNFXFUDOU-RFZPGFLSSA-N (3r,4r)-4-aminopiperidin-3-ol Chemical compound N[C@@H]1CCNC[C@H]1O UVBKPWNFXFUDOU-RFZPGFLSSA-N 0.000 description 1
- ZCZJKVCIYONNJR-QWWZWVQMSA-N (3r,4r)-4-aminopyrrolidin-3-ol Chemical compound N[C@@H]1CNC[C@H]1O ZCZJKVCIYONNJR-QWWZWVQMSA-N 0.000 description 1
- PBQHDTRHGNGTLZ-RFZPGFLSSA-N (3s,4r)-4-aminooxan-3-ol Chemical compound N[C@@H]1CCOC[C@H]1O PBQHDTRHGNGTLZ-RFZPGFLSSA-N 0.000 description 1
- HQVKXDYSIGDGSY-QWWZWVQMSA-N (3s,4r)-4-aminooxolan-3-ol Chemical compound N[C@@H]1COC[C@H]1O HQVKXDYSIGDGSY-QWWZWVQMSA-N 0.000 description 1
- LNYNSKJTNYTLNL-QWWZWVQMSA-N (3s,4s)-4-aminothiolan-3-ol Chemical compound N[C@@H]1CSC[C@H]1O LNYNSKJTNYTLNL-QWWZWVQMSA-N 0.000 description 1
- AOJURBVPQULQLT-UHFFFAOYSA-N (4,4-dimethylcyclohexa-1,5-dien-1-yl)-phenylmethanone Chemical compound C1=CC(C)(C)CC=C1C(=O)C1=CC=CC=C1 AOJURBVPQULQLT-UHFFFAOYSA-N 0.000 description 1
- CTBGCMPGQFIXNO-UHFFFAOYSA-N (5,5-dimethylcyclohexa-1,3-dien-1-yl)-phenylmethanone Chemical compound C1=CC(C)(C)CC(C(=O)C=2C=CC=CC=2)=C1 CTBGCMPGQFIXNO-UHFFFAOYSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JVWOABSIBLELKT-UHFFFAOYSA-N 1,10-phenanthroline-5,6-dicarboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C(O)=O)C3=CC=CN=C3C2=N1 JVWOABSIBLELKT-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- JCHBFSBFSWWPIN-UHFFFAOYSA-N 1,2-dichloro-1-methyl-4-propan-2-ylcyclohexane Chemical compound CC(C)C1CCC(C)(Cl)C(Cl)C1 JCHBFSBFSWWPIN-UHFFFAOYSA-N 0.000 description 1
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 1
- SQPJFSDJLQFTRT-UHFFFAOYSA-N 1,4-dihydroxynaphthalene-2,3-dicarboxylic acid Chemical compound C1=CC=C2C(O)=C(C(O)=O)C(C(=O)O)=C(O)C2=C1 SQPJFSDJLQFTRT-UHFFFAOYSA-N 0.000 description 1
- PYYCVJQREOKYDO-UHFFFAOYSA-N 1-[(1-carboxycyclohexyl)diazenyl]cyclohexane-1-carboxylic acid Chemical compound C1CCCCC1(C(O)=O)N=NC1(C(=O)O)CCCCC1 PYYCVJQREOKYDO-UHFFFAOYSA-N 0.000 description 1
- KODLUXHSIZOKTG-UHFFFAOYSA-N 1-aminobutan-2-ol Chemical compound CCC(O)CN KODLUXHSIZOKTG-UHFFFAOYSA-N 0.000 description 1
- ZRUPXAZUXDFLTG-UHFFFAOYSA-N 1-aminopentan-2-ol Chemical compound CCCC(O)CN ZRUPXAZUXDFLTG-UHFFFAOYSA-N 0.000 description 1
- QSSXJPIWXQTSIX-UHFFFAOYSA-N 1-bromo-2-methylbenzene Chemical compound CC1=CC=CC=C1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 1
- RINOYHWVBUKAQE-UHFFFAOYSA-N 1-iodo-2-methylbenzene Chemical compound CC1=CC=CC=C1I RINOYHWVBUKAQE-UHFFFAOYSA-N 0.000 description 1
- MGBRGNWARSQECY-UHFFFAOYSA-N 1-methoxy-3-methyl-2-nitrobenzene Chemical compound COC1=CC=CC(C)=C1[N+]([O-])=O MGBRGNWARSQECY-UHFFFAOYSA-N 0.000 description 1
- SHMKKPZGLDISGT-UHFFFAOYSA-N 1-methyl-2-(4-methylphenyl)benzene Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1C SHMKKPZGLDISGT-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- QFGCFKJIPBRJGM-UHFFFAOYSA-N 12-[(2-methylpropan-2-yl)oxy]-12-oxododecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCCCC(O)=O QFGCFKJIPBRJGM-UHFFFAOYSA-N 0.000 description 1
- ZHKJHQBOAJQXQR-UHFFFAOYSA-N 1H-azirine Chemical compound N1C=C1 ZHKJHQBOAJQXQR-UHFFFAOYSA-N 0.000 description 1
- PIPQOFRJDBZPFR-UHFFFAOYSA-N 1h-benzimidazole-5,6-dicarboxylic acid Chemical compound C1=C(C(O)=O)C(C(=O)O)=CC2=C1NC=N2 PIPQOFRJDBZPFR-UHFFFAOYSA-N 0.000 description 1
- ZEVWQFWTGHFIDH-UHFFFAOYSA-N 1h-imidazole-4,5-dicarboxylic acid Chemical compound OC(=O)C=1N=CNC=1C(O)=O ZEVWQFWTGHFIDH-UHFFFAOYSA-N 0.000 description 1
- GSTYAKYRWMILGV-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrole;1h-pyrrole;pyrrolidine Chemical compound C1CCNC1.C1CC=CN1.C=1C=CNC=1 GSTYAKYRWMILGV-UHFFFAOYSA-N 0.000 description 1
- 125000004959 2,6-naphthylene group Chemical group [H]C1=C([H])C2=C([H])C([*:1])=C([H])C([H])=C2C([H])=C1[*:2] 0.000 description 1
- XSNWHFKLVRFZIH-UHFFFAOYSA-N 2-(4-carboxyphenyl)-5-methoxybenzoic acid Chemical compound OC(=O)C1=CC(OC)=CC=C1C1=CC=C(C(O)=O)C=C1 XSNWHFKLVRFZIH-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical class C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- PPZYHOQWRAUWAY-UHFFFAOYSA-N 2-[2-(carboxymethoxy)phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC=C1OCC(O)=O PPZYHOQWRAUWAY-UHFFFAOYSA-N 0.000 description 1
- CCQMORVULNZXIA-UHFFFAOYSA-N 2-[2-(carboxymethylsulfanyl)ethylsulfanyl]acetic acid Chemical compound OC(=O)CSCCSCC(O)=O CCQMORVULNZXIA-UHFFFAOYSA-N 0.000 description 1
- SLWIPPZWFZGHEU-UHFFFAOYSA-N 2-[4-(carboxymethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(CC(O)=O)C=C1 SLWIPPZWFZGHEU-UHFFFAOYSA-N 0.000 description 1
- CABMTIJINOIHOD-UHFFFAOYSA-N 2-[4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]quinoline-3-carboxylic acid Chemical compound N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O CABMTIJINOIHOD-UHFFFAOYSA-N 0.000 description 1
- OKYOTYMRDBFYNX-UHFFFAOYSA-N 2-[[5-[3-[3-[[carboxymethyl(methyl)amino]methyl]-4-hydroxy-5-methylphenyl]-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]-2-hydroxy-3-methylphenyl]methyl-methylamino]acetic acid Chemical compound CC1=C(O)C(CN(CC(O)=O)C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(C)CC(O)=O)C(O)=C(C)C=2)=C1 OKYOTYMRDBFYNX-UHFFFAOYSA-N 0.000 description 1
- LJCGQQOZNDXTKI-UHFFFAOYSA-N 2-[acetamido(carboxymethyl)amino]acetic acid Chemical compound CC(=O)NN(CC(O)=O)CC(O)=O LJCGQQOZNDXTKI-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- VKPHHYUEMRNFSX-UHFFFAOYSA-N 2-aminobutan-2-ol Chemical compound CCC(C)(N)O VKPHHYUEMRNFSX-UHFFFAOYSA-N 0.000 description 1
- ULAXUFGARZZKTK-UHFFFAOYSA-N 2-aminopentan-1-ol Chemical compound CCCC(N)CO ULAXUFGARZZKTK-UHFFFAOYSA-N 0.000 description 1
- JPGZDACJIPHKML-UHFFFAOYSA-N 2-aminopentan-3-ol Chemical compound CCC(O)C(C)N JPGZDACJIPHKML-UHFFFAOYSA-N 0.000 description 1
- BKMMTJMQCTUHRP-UHFFFAOYSA-N 2-aminopropan-1-ol Chemical compound CC(N)CO BKMMTJMQCTUHRP-UHFFFAOYSA-N 0.000 description 1
- GPNNOCMCNFXRAO-UHFFFAOYSA-N 2-aminoterephthalic acid Chemical compound NC1=CC(C(O)=O)=CC=C1C(O)=O GPNNOCMCNFXRAO-UHFFFAOYSA-N 0.000 description 1
- DHPUIKWBNXTXOB-UHFFFAOYSA-N 2-bromo-1-methoxy-4-methylbenzene Chemical compound COC1=CC=C(C)C=C1Br DHPUIKWBNXTXOB-UHFFFAOYSA-N 0.000 description 1
- QPBGNSFASPVGTP-UHFFFAOYSA-N 2-bromoterephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(Br)=C1 QPBGNSFASPVGTP-UHFFFAOYSA-N 0.000 description 1
- NPRYHWFMGPYJIY-UHFFFAOYSA-N 2-cyclohexyloxirane Chemical compound C1OC1C1CCCCC1 NPRYHWFMGPYJIY-UHFFFAOYSA-N 0.000 description 1
- CJJLEUQMMMLOFI-UHFFFAOYSA-N 2-methoxy-4-methylaniline Chemical compound COC1=CC(C)=CC=C1N CJJLEUQMMMLOFI-UHFFFAOYSA-N 0.000 description 1
- GAKLFAZBKQGUBO-UHFFFAOYSA-N 2-methyl-3-nitrophenol Chemical compound CC1=C(O)C=CC=C1[N+]([O-])=O GAKLFAZBKQGUBO-UHFFFAOYSA-N 0.000 description 1
- DTFKRVXLBCAIOZ-UHFFFAOYSA-N 2-methylanisole Chemical compound COC1=CC=CC=C1C DTFKRVXLBCAIOZ-UHFFFAOYSA-N 0.000 description 1
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 1
- LVFFZQQWIZURIO-UHFFFAOYSA-N 2-phenylbutanedioic acid Chemical compound OC(=O)CC(C(O)=O)C1=CC=CC=C1 LVFFZQQWIZURIO-UHFFFAOYSA-N 0.000 description 1
- JWOLVTCKNXRZOD-UHFFFAOYSA-N 2-phenylcyclohexa-2,4-diene-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CC=CC=C1C1=CC=CC=C1 JWOLVTCKNXRZOD-UHFFFAOYSA-N 0.000 description 1
- GCOOGCQWQFRJEK-UHFFFAOYSA-N 2-thiophen-3-ylpropanedioic acid Chemical compound OC(=O)C(C(O)=O)C=1C=CSC=1 GCOOGCQWQFRJEK-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- WZHHYIOUKQNLQM-UHFFFAOYSA-N 3,4,5,6-tetrachlorophthalic acid Chemical compound OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C(O)=O WZHHYIOUKQNLQM-UHFFFAOYSA-N 0.000 description 1
- OUJCFCNZIUTYBH-UHFFFAOYSA-N 3,4-diphenylfuran-2,5-dione Chemical compound O=C1OC(=O)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OUJCFCNZIUTYBH-UHFFFAOYSA-N 0.000 description 1
- OXTNCQMOKLOUAM-UHFFFAOYSA-N 3-Oxoglutaric acid Chemical compound OC(=O)CC(=O)CC(O)=O OXTNCQMOKLOUAM-UHFFFAOYSA-N 0.000 description 1
- FVXBTPGZQMNAEZ-UHFFFAOYSA-N 3-amino-2-methylpropan-1-ol Chemical compound NCC(C)CO FVXBTPGZQMNAEZ-UHFFFAOYSA-N 0.000 description 1
- AGMZSYQMSHMXLT-UHFFFAOYSA-N 3-aminobutan-1-ol Chemical compound CC(N)CCO AGMZSYQMSHMXLT-UHFFFAOYSA-N 0.000 description 1
- BKFGLDUWYUYHRF-UHFFFAOYSA-N 3-aminopentan-2-ol Chemical compound CCC(N)C(C)O BKFGLDUWYUYHRF-UHFFFAOYSA-N 0.000 description 1
- JPKBIODDVOUHAD-UHFFFAOYSA-N 3-methoxy-2-methylbenzonitrile Chemical compound COC1=CC=CC(C#N)=C1C JPKBIODDVOUHAD-UHFFFAOYSA-N 0.000 description 1
- QIORDSKCCHRSSD-UHFFFAOYSA-N 3-methyl-2-nitrophenol Chemical compound CC1=CC=CC(O)=C1[N+]([O-])=O QIORDSKCCHRSSD-UHFFFAOYSA-N 0.000 description 1
- BOHCMQZJWOGWTA-UHFFFAOYSA-N 3-methylbenzonitrile Chemical compound CC1=CC=CC(C#N)=C1 BOHCMQZJWOGWTA-UHFFFAOYSA-N 0.000 description 1
- AYKYXWQEBUNJCN-UHFFFAOYSA-N 3-methylfuran-2,5-dione Chemical compound CC1=CC(=O)OC1=O AYKYXWQEBUNJCN-UHFFFAOYSA-N 0.000 description 1
- FLFLZYYDLIKGJQ-UHFFFAOYSA-N 3-nitro-1,8-naphthalic anhydride Chemical compound C1=CC2=CC([N+](=O)[O-])=CC(C(=O)OC3=O)=C2C3=C1 FLFLZYYDLIKGJQ-UHFFFAOYSA-N 0.000 description 1
- HEGLMCPFDADCAQ-UHFFFAOYSA-N 4,7-dichloro-2-benzofuran-1,3-dione Chemical compound ClC1=CC=C(Cl)C2=C1C(=O)OC2=O HEGLMCPFDADCAQ-UHFFFAOYSA-N 0.000 description 1
- NAXUFNXWXFZVSI-UHFFFAOYSA-N 4-aminobutan-2-ol Chemical compound CC(O)CCN NAXUFNXWXFZVSI-UHFFFAOYSA-N 0.000 description 1
- IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- JKZSIEDAEHZAHQ-UHFFFAOYSA-N 4-methoxyphthalic acid Chemical compound COC1=CC=C(C(O)=O)C(C(O)=O)=C1 JKZSIEDAEHZAHQ-UHFFFAOYSA-N 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- ROFZMKDROVBLNY-UHFFFAOYSA-N 4-nitro-2-benzofuran-1,3-dione Chemical compound [O-][N+](=O)C1=CC=CC2=C1C(=O)OC2=O ROFZMKDROVBLNY-UHFFFAOYSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- ULSOWUBMELTORB-UHFFFAOYSA-N 5,6-dichloro-2-benzofuran-1,3-dione Chemical compound C1=C(Cl)C(Cl)=CC2=C1C(=O)OC2=O ULSOWUBMELTORB-UHFFFAOYSA-N 0.000 description 1
- GBBPFLCLIBNHQO-UHFFFAOYSA-N 5,6-dihydro-4h-cyclopenta[c]furan-1,3-dione Chemical compound C1CCC2=C1C(=O)OC2=O GBBPFLCLIBNHQO-UHFFFAOYSA-N 0.000 description 1
- LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 description 1
- NQXUSSVLFOBRSE-UHFFFAOYSA-N 5-methyl-2-nitrophenol Chemical compound CC1=CC=C([N+]([O-])=O)C(O)=C1 NQXUSSVLFOBRSE-UHFFFAOYSA-N 0.000 description 1
- MMVIDXVHQANYAE-UHFFFAOYSA-N 5-nitro-2-benzofuran-1,3-dione Chemical compound [O-][N+](=O)C1=CC=C2C(=O)OC(=O)C2=C1 MMVIDXVHQANYAE-UHFFFAOYSA-N 0.000 description 1
- NBDAHKQJXVLAID-UHFFFAOYSA-N 5-nitroisophthalic acid Chemical compound OC(=O)C1=CC(C(O)=O)=CC([N+]([O-])=O)=C1 NBDAHKQJXVLAID-UHFFFAOYSA-N 0.000 description 1
- SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 1
- IXXLNJFXTNXULU-UHFFFAOYSA-N CC1=C(C=CC=C1)C1=CC=C(C=C1)C.CC=1C(=C(C=CC1)C1=CC=CC=C1)C Chemical compound CC1=C(C=CC=C1)C1=CC=C(C=C1)C.CC=1C(=C(C=CC1)C1=CC=CC=C1)C IXXLNJFXTNXULU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N Dipicolinic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- IMLXLGZJLAOKJN-IZLXSQMJSA-N N[C@H]1CC[C@H](O)CC1 Chemical compound N[C@H]1CC[C@H](O)CC1 IMLXLGZJLAOKJN-IZLXSQMJSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- GRSMWKLPSNHDHA-UHFFFAOYSA-N Naphthalic anhydride Chemical compound C1=CC(C(=O)OC2=O)=C3C2=CC=CC3=C1 GRSMWKLPSNHDHA-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 238000005937 allylation reaction Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- HVZMEJKDXFWCMF-UHFFFAOYSA-N aziridine oxirane Chemical compound N1CC1.O1CC1 HVZMEJKDXFWCMF-UHFFFAOYSA-N 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 description 1
- QPRFAFKPBOLMDI-UHFFFAOYSA-N bis(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)C1=CC=CC=C1C QPRFAFKPBOLMDI-UHFFFAOYSA-N 0.000 description 1
- CGXDIDXEMHMPIX-UHFFFAOYSA-N bis(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)C=2C=C(C)C=CC=2)=C1 CGXDIDXEMHMPIX-UHFFFAOYSA-N 0.000 description 1
- ZWPWLKXZYNXATK-UHFFFAOYSA-N bis(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(C)C=C1 ZWPWLKXZYNXATK-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 230000004706 cardiovascular dysfunction Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- FBOZORITEYCRMG-UHFFFAOYSA-N cyclobutane;oxetane Chemical compound C1CCC1.C1COC1 FBOZORITEYCRMG-UHFFFAOYSA-N 0.000 description 1
- YUPGJGXCFPRSTK-UHFFFAOYSA-N cyclohexa-1,3-diene;cyclohexene Chemical compound C1CCC=CC1.C1CC=CC=C1 YUPGJGXCFPRSTK-UHFFFAOYSA-N 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- RLWFMZKPPHHHCB-UHFFFAOYSA-N cyclopropane-1,2-dicarboxylate;hydron Chemical compound OC(=O)C1CC1C(O)=O RLWFMZKPPHHHCB-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007275 deallylation reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical class CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 1
- MPFLRYZEEAQMLQ-UHFFFAOYSA-N dinicotinic acid Chemical compound OC(=O)C1=CN=CC(C(O)=O)=C1 MPFLRYZEEAQMLQ-UHFFFAOYSA-N 0.000 description 1
- 229950004394 ditiocarb Drugs 0.000 description 1
- PFLVWSJYEFPQSV-UHFFFAOYSA-N docosanedioic acid;hexadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCC(O)=O.OC(=O)CCCCCCCCCCCCCCCCCCCCC(O)=O PFLVWSJYEFPQSV-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- LVPMIMZXDYBCDF-UHFFFAOYSA-N isocinchomeronic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)N=C1 LVPMIMZXDYBCDF-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- MJIVRKPEXXHNJT-UHFFFAOYSA-N lutidinic acid Chemical compound OC(=O)C1=CC=NC(C(O)=O)=C1 MJIVRKPEXXHNJT-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000004702 methyl esters Chemical group 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- CHDRADPXNRULGA-UHFFFAOYSA-N naphthalene-1,3-dicarboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC(C(O)=O)=C21 CHDRADPXNRULGA-UHFFFAOYSA-N 0.000 description 1
- DFFZOPXDTCDZDP-UHFFFAOYSA-N naphthalene-1,5-dicarboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1C(O)=O DFFZOPXDTCDZDP-UHFFFAOYSA-N 0.000 description 1
- VAWFFNJAPKXVPH-UHFFFAOYSA-N naphthalene-1,6-dicarboxylic acid Chemical compound OC(=O)C1=CC=CC2=CC(C(=O)O)=CC=C21 VAWFFNJAPKXVPH-UHFFFAOYSA-N 0.000 description 1
- WPUMVKJOWWJPRK-UHFFFAOYSA-N naphthalene-2,7-dicarboxylic acid Chemical compound C1=CC(C(O)=O)=CC2=CC(C(=O)O)=CC=C21 WPUMVKJOWWJPRK-UHFFFAOYSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QUMITRDILMWWBC-UHFFFAOYSA-N nitroterephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C([N+]([O-])=O)=C1 QUMITRDILMWWBC-UHFFFAOYSA-N 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- AHWWYXLUWXDFLF-UHFFFAOYSA-N piperazine-2,6-dicarboxylic acid Chemical compound OC(=O)C1CNCC(C(O)=O)N1 AHWWYXLUWXDFLF-UHFFFAOYSA-N 0.000 description 1
- YDYHBIMKHWQBFR-UHFFFAOYSA-N piperidine-3,3-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCCNC1 YDYHBIMKHWQBFR-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- ZUCRGHABDDWQPY-UHFFFAOYSA-N pyrazine-2,3-dicarboxylic acid Chemical compound OC(=O)C1=NC=CN=C1C(O)=O ZUCRGHABDDWQPY-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- XIEOKRXVAACBHI-UHFFFAOYSA-N pyrimidine-4,6-dicarboxylic acid Chemical compound OC(=O)C1=CC(C(O)=O)=NC=N1 XIEOKRXVAACBHI-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- ZMRHBJQLCDZMAH-UHFFFAOYSA-M sodium chloride hydrate hydrochloride Chemical compound [OH-].[Na+].Cl.Cl ZMRHBJQLCDZMAH-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UFDHBDMSHIXOKF-UHFFFAOYSA-N tetrahydrophthalic acid Natural products OC(=O)C1=C(C(O)=O)CCCC1 UFDHBDMSHIXOKF-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- TXXHDPDFNKHHGW-ZPUQHVIOSA-N trans,trans-muconic acid Chemical compound OC(=O)\C=C\C=C\C(O)=O TXXHDPDFNKHHGW-ZPUQHVIOSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 238000007514 turning Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Definitions
- the present invention relates to a novel method for the preparation of balanol analogues using a specially developed combinatorial chemistry scheme.
- the scheme is also especially suited for the preparation of libraries of balanol analogues.
- the present invention gives access to novel classes of compounds which may have interesting and unexpected structural and functional features, and, thus, the present invention also relates to the use of the libraries for screening purposes and to the use of novel compounds as medicaments for the treatment of various diseases.
- PKC Protein kinase C
- PKC Protein kinase C
- a family of serine/threonine specific kinases which are involved in a variety of processes including signal transduction, cell proliferation and cell differentiation.
- Agents that inhibit PKC may have wide ranging therapeutic potential since activated PKC has been implicated in numerous disease processes. These include some widespread and severe diseases such as cancer, inflammation, cardiovascular dysfunctions, diabetic complications, asthma, central nervous system disorders and HIV infection.
- Balanol is a fungal metabolite, which has attracted significant attention because it possesses high PKC inhibiting activity. Furthermore, balanol has a relatively favourable therapeutic index compared to staurosporin, which is another known PKC inhibitor.
- the literature contains several examples of total syntheses of balanol in solution (Lampe, J. W.; Hughes, P. F.; Bigger, C. K.; Smith, S. H.; Hu, H. J. Org. Chem. 1994, 59, 5147-5148, Lampe, J. W.; Hughes, P. F.;
- the aim of the present invention is to provide a simplified synthetic scheme for the preparation of balanol analogues using solid-phase synthesis methodologies. It is believed that a novel solid phase method for the preparation of balanol analogues may provide easier access to known analogues and also provide hitherto unknown balanol analogues. The synthetic scheme will also allow for the easy preparation of combinatorial libraries of balanol analogues.
- the present invention provides a method for the preparation of balanol derivatives of the following general formula I:
- each of A and B designates an organic biradical
- each of L 1 and L 2 independently designates -NR 5 - or -O-
- each R 5 independently is selected from hydrogen, optionally substituted C 1-20 -alkyl, optionally substituted C 1-20 -alkenyl, optionally substituted C 1-20 -alkadienyl, optionally substituted C 1-20 -alkatrienyl, optionally substituted aryl, and optionally substituted heteroaryl
- R 3 designates an additional bond to B (whereby B becomes a triradical)
- D designates optionally substituted aryl or optionally substituted heteroaryl
- the method comprises the following steps:
- the present invention also provides a method for the preparation of a multi-dimensional array of compounds, ⁇ A ⁇ - ⁇ B ⁇ - ⁇ D ⁇ , consisting of at least four compounds, preferably in the range of 6-200 compounds, more preferably in the range of 6-100 compounds, in particular in the range of 8-64 compounds each having the general formula 1 as defined above, comprising the following steps:
- C 1-20 -alkyl is intended to mean a linear, cyclic or branched hydrocarbon group having 1 to 20 carbon atoms, such as methyl, ethyl, propyl, iso-propyl cyclopropyl, butyl, tert-butyl, iso-butyl, cyclobutyl, pentyl cyclopentyl, hexyl, cyclohexyl, hexadecyl, heptadecyl, octadecyl, nonadecyl.
- C 1-6 -alkyl is intended to mean a linear, cyclic or branched hydrocarbon group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl iso-propyl, pentyl, cyclopentyl, hexyl, cyclohexyl.
- C 1-4 -alkyl is intended to cover linear, cyclic or branched hydrocarbon groups having 1 to 4 carbon atoms, e. g. methyl, ethyl, propyl, iso-propyl, cyclopropyl, butyl, iso-butyl, tert-butyl, cyclobutyl.
- C 1 -6 -alkyl are methyl, ethyl, propyl, iso-propyl, butyl, tert-butyl, iso-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, in particular methyl, ethyl, propyl, iso-propyl, tertbutyl, iso-butyl and cyclohexyl.
- Preferred examples of "C 1-4 -alkyl” are methyl, ethyl, propyl, iso ⁇ propyl, butyl, tert-butyl, and iso-butyl
- C 2-20 -alkenyl C 4-20 -alkadienyl
- C 6-20 -alkatrienyl are intended to mean a linear, cyclic or branched hydrocarbon group having 2 to 20, 4 to 20, and 6 to 20, carbon atoms, respectively, and comprising one, two, and three unsaturated bonds, respectively.
- alkenyl groups are vinyl, allyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, heptadecaenyl.
- alkadienyl groups are butadienyl, pentadienyl, hexadienyl, heptadienyl, heptadecadienyl.
- alkatrienyl groups are hexatrienyl, heptatrienyl, octatrienyl, and heptadecatnenyl.
- Preferred examples of alkenyl are vinyl, allyl, butenyl, especially allyl
- C 2-20 -alkynyl is intended to mean a linear or branched hydrocarbon group having 2 to 20 carbon atoms and comprising a triple bond. Examples hereof are ethynyl, propynyl, butynyl, octynyl, and dodecaynyl. In the present context, i. e.
- alkyl alkenyl
- alkadienyl alkadienyl
- alkatnenyl alkynyl
- alkynyl optionally substituted is intended to mean that the group in question may be substituted one or several times, preferably 1-3 times, with group(s) selected from hydroxy (which when bound to an unsaturated carbon atom may be present in the tautomeric keto form), C 1-6 -alkoxy (i.e.
- alkyl-oxy C 2-6 -alkenyloxy, carboxy, oxo (forming a keto or aldehyde functionality), C 1-6 -alkoxycarbonyl, C 1-6 -alkylcarbonyl, formyl, aryl, aryloxycarbonyl aryloxy, arylcarbonyl, heteroaryl, heteroaryloxycarbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C 1-6 -alkyl)amino, carbamoyl, mono- and di(C 1-6 -alkyl)aminocarbonyl, amino- C 1-6 -alkyl-aminocarbonyl, mono- and di(C 1-6 -alkyl)amino-C 1-6 -alkyl-aminocarbonyl, C 1-6 -alkylcarbonylamino, guanidino, carbamido, C 1-6 -alkanoyloxy, sulphono, C
- the substituents are selected from hydroxy, C 1-6 -alkoxy, carboxy, C 1-6 -alkoxycarbonyl C 1-6 -alkylcarbonyl, formyl, aryl, aryloxycarbonyl, arylcarbonyl, heteroaryl, amino, mono- and di(C 1-6 -alkyl)amino, carbamoyl, mono- and di(C 1-6 -alkyl)aminocarbonyl, amino-C 1-6 -alkyl-amino- carbonyl, mono- and di(C 1-6 -alkyl)amino-C 1-6 -alkyl-aminocarbonyl, C 1-6 -alkylcarbonylamino, carbamido, trihalogen-C 1-4 -alkyl, halogen such as fluoro, chloro, bromo or lodo, where aryl and heteroaryl may be substituted 1-5 times, preferably 1-3 times, with C 1-4 -alky
- aryl is intended to mean a fully or partially aromatic carbocyclic ring or ring system, such as phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracyl phenanthracyl, pyrenyl, benzopyrenyl, fluorenyl and xanthenyl, among which phenyl is a preferred example.
- heteroaryl groups are oxazolyl, isoxazolyl, thiazolyl, iso-thiazolyl, pyrrolyl, lmidazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, pipendinyl, coumaryl, furyl, quinolyl, benzothiazolyl, benzotriazolyl, benzodiazolyl, benzooxozolyl, phthalazinyl, phthalanyl, triazolyl, tetrazolyl, isoquinolyl, acridiny
- non-aromatic carbocyclic and heterocyclic group is intended to cover rings comprising carbon atoms only (carbocyclic) or carbon atoms together with
- heteroatoms are typically selected from nitrogen, oxygen, and sulphur.
- Such groups involve no unsaturated bonds or one or several unsaturated bonds, however, if present, situated in such a way that no aromatic ⁇ -electron system arises. It should be understood that the radical positions are situated directly on the ring in case of a biradical arising from such a group.
- non-aromatic carbocyclic and heterocyclic groups are oxazetane, diazetane, thiazetane, oxazolane, lmidazohdine, thiazolane, oxazilane, hexahydropyridazine, thiazilane, oxazepane, diazepane, thiazepane, oxazocane, diazocane, thiazocane, tetrahydrofuran, dihydrofuran, pyrrolidine, tetrahydrothiophen, tetrahydropyran, piperidine, tetrahydrothiopyran , oxepane, azepane, thiepane, oxocane, azocane, thiocane, cyclopropane, oxirane, azindine, cyclopropene, azinne, cyclobutane ox
- oxirane azindine, azirine, oxetane, 2-azetidinone, 1,3-lactone, pyrohdine, pyroline, pyrrole, pyrolhdone, pyrollidione, oxirane, dioxirane, morpholine, piperidine, ⁇ -valerolactam (2-pipendone), 1 ,5-lactone, piperidione, tropolone, 1,6-lactam, azepine, dihydroazepine, tetrahydroazepine, and
- hexahydroazepine Particularly preferred examples are 2-azetidinone, 1,3-lactone, pyrolhdone 1,5-lactam, 1,5-lactone, tropolone, 1,6-lactam, azepine, dihydroazepine, tetrahydroazepine, and hexahydroazepine.
- aryl in connection with the terms “aryl”, “heteroaryl”, and “non-aromatic carbocyclic and heterocyclic group”
- the term “optionally substituted” is intended to mean that the group in question may be substituted one or several times, preferably 1-5 times in particular 1-3 times) with group(s) selected from hydroxy (which when present in an enol system may be represented in the tautomeric keto form), C 1-6 -alkyl C 1-6 -alkoxy, oxo (which may be represented in the tautomeric enol form), carboxy, C 1-6 -alkoxycarbonyl, C 1-6 -alkylcarbonyl, formyl, aryl, aryloxy, aryloxycarbonyl, arylcarbonyl, heteroaryl, amino, mono- and di(C 1-6 -alkyl)amino carbamoyl, mono- and di(C 1-6 -alkyl)aminocarbonyl, arm
- Preferred examples are hydroxy, C 1-6 -alkyl, C 1-6 -alkoxy, carboxy, C 1-6 -alkoxycarbonyl, C 1-6 -alkylcarbonyl, aryl, amino, mono- and di(C 1-6 -alkyl)amino and halogen such as fluoro, chloro, bromo or lodo, wherein aryl and heteroaryl may be substituted as above.
- organic biradical and "biradical” are intended to have the meaning normally associated therewith.
- biradicals may be derived from practically any organic molecule from which two (non-geminal and theoretical) hydrogen atoms are removed.
- interesting biradicals are either linear or cyclic or comprises two or more domains selected from linear and cyclic sub-biradicals.
- Illustrative examples of combined biradicals comprising domains which have both linear and cyclic character are phenylene-carbonyl-phenylene, methylene-phenylene-methyleneoxy, and methylene-phenylene.
- the biradical may also consist of or comprise one or more cyclic elements, in particular 5- or 6-or 7-membered cyclic elements.
- oxygen or sulphur oxygen or sulphur.
- Examples of cyclic biradicals are biradicals of optionally substituted aryl groups and optionally substituted heteroaryl groups as well as biradicals of optionally substituted non-aromatic carbocyclic and heterocyclic groups.
- the compounds of the general formula I include possible salts thereof, of which pharmaceutically acceptable salts are especially relevant.
- Salts include acid addition salts and basic salts. Examples hereof are hydrochloride salts, sodium salts, calcium salts, potassium salts, etc.
- Pharmaceutically acceptable salts are, e.g., those described in Remington's Pharmaceutical Sciences, 17. Ed. Alfonso R.Gennaro (Ed ), Mack Publishing Company, Easton, PA, U.S.A., 1985.
- final products may also be present in hydrate form.
- the benzoic acid building block may be represented by any aromatic and heteroaromatic carboxylic acid, and that the diacid may be any other dicarboxylic acid of linear, cyclic, non-aromatic or aromatic origin .
- K designates OH, O , OR", NH2, NHR, or NRR', in particular OH, methoxy, or NH2, where R and R' are selected from C 1-6 -alkyl and benzyl, and R" is selected from C 1-6 -alkyl, C 2-6 -alkenyl, phenyl, and benzyl.
- this may be an aliphatic biradical of the formula
- biradical A are biradicals either comprising or consisting of cyclic biradicals of the following radicals phenyl, naphthyl, anthracyl, pyrenyl, benzopyrenyl, phenoxazonyl, N 8 -phenoxazonyl, quinolyl, benzophenazinyl, ethidium and fluorenyl Especially preferred examples are naphthyl, benzopyrenyl, phenoxazonyl, N 8 -phenoxazonyl, quinolyl benzophenazinyl, ethidium and fluorenyl, and/or comprising or consisting of linear biradicals of the formula -(CR 3 R 4 ) n -, where each of R 3 and R 4 independently are selected from optional
- aromatic and heteroaromatic biradicals, A may be substituted with one or more groups selected from the same groups as defined above as substituents for the aryl and heteroaryl groups.
- 2,2'-biquinoline-4,4'-dicarboxylic acid 5-nitro-isophthalic acid, 2-amino-terephthalic acid, 2-bromo-terephthalic acid, 2-nitro-terephthalic acid, 3,6-dichloro-phthalic acid anhydride, 4,5-dichloro-phthalic acid anhydride, 3-nitro-phthalic acid anhydride, 4-nitro-phthalic acid anhydride, homophthalic acid, 4,4'-biphenyl-dicarboxylic acid, 2,2 -biphenyl-dicarboxylic acid, 2,3-naphthalene-dicarboxylic acid, 2,6-naphthalene-dicarboxylic acid, 1,8-naphthalene-dicarboxylic acid anhydride, 3-nitro-1,8-naphthalene-dicarboxylic acid anhydride, 1,2-phenylendioxy-diacetic acid, embonic acid, 5,5'-dithiobis-(2-nitrobenz
- oxalic acid malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, undecanedioic acid, dodecanedioic acid, tetradecanedioic acid, hexadecanedioic acid docosanedioic acid, trans, trans-muconic acid, methylmaleic acid, methylmaleic acid anhydride, (+)- and (-)-camphonc acid, 1,3-acetone dicarboxylic acid, N-(acetamido)-iminodiacetic acid, L-aspartic acid, S-carboxymethyl-L-cysteine, 2,2'-(ethylendithio)-diacetic acid, malic acid (+ and -), D-penicillamme, phenylsuccinic acid, N-(phosphonomethyl)-lminodiacetic acid,
- R 3 , R 4 and n are as defined above for A.
- biradical B are, e g , biradicals of the following non-aromatic carbocyclic compounds cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cycloheptane and cyclooctane, the following aromatic or non-aromatic heterocyclic compounds epoxides, aziridines, thioepoxides, oxazetane, diazetane, thiazetane, oxazolane, lmidazolidine, thiazolane, oxazilane, hexahydropyridazine, thiazilane, oxazepane, diazepane, thiazepane, oxazocane, diazocane, thiazocane, tetrahydrofuran, dihydrofuran, pyrrolidine,
- the aminoalcohol When the aminoalcohol is selected from the group of non-aromatic carbocyclic compounds or heterocyclic compounds the hydroxy- and amino-function can be positioned 1 ,2-, 1,3-, 1 ,4- or 1,5-, where applicable, to each other as well as the stereochemical environment of the amino and alcohol groups can be positioned either in a cis-configuration where the two substituents are on the same side of the ring or could be positioned trans-configuration where the two substituents are on the different side of the ring system.
- different enantiomers (mirror images) and diastereoisomers can exist as an inherent result of the chirahty in such substituted non-aromatic carbocyclic compounds or heterocyclic compounds.
- especially preferred examples are aminoalcohols derived from non-aromatic carbocyclic and heterocyclic compounds where the hydroxy and amino function are positioned 1,2 or 1,3 relative to each other, especially 1 ,2 to each other.
- aminoalcohols derived from non-aromatic carbocyclic compounds are 2-aminoethanol, 1-amino-2-propanol, 3-amino- 1-propanol, 2-amino- 1-propanol, 2-amino-2-methyl- 1-propanol, 1-amino-2-methyl-2-propanol, 3-amino-2-methyl- 1-propanol, 2-amino-1-butanol, 1 -amino-2-butanol, 3-amino-3-butanol, 3-amino- 1-butanol, 4-amino-2-butanol, cis-2-amino- 1-cyclobutanol, trans-2-amino- 1-cyclobutanol, 5-amino-1-pentanol, 2-amino- 1 -pentanol, 3-amino-2-pentanol, 2-amino-3-pentanol, 1-amino-2-pentanol,
- aminoalcohols derived from heterocyclic compounds are cis-4-amino-3-hydroxy-pyrolidine, trans-4-amino-3- hydroxy-pyrrolidine, cis-4-amino-3-hydroxy-tetrahydrofuran, trans-4-amino-3-hydroxy- tetrahydrofuran, cis-4-amino-3-hydroxy-tetrahydrothiophen, trans-4-amino-3-hydroxy-tetrahydrothiophen, cis-3-amino-4-hydroxy-piperidine, trans-3-amino-4-hydroxy-piperidine, cis-4-amino-3-hydroxy-piperidine, trans-4-amino-3-hydroxy-piperidine, cis-5-amino-3-hydroxy-piperidine, trans-5-amino-3-hydroxy-pipendine, cis-4-amino-3-hydroxytetrahydro-2H-pyrane, trans-4-amino-3-hydroxy-tetrahydro
- the synthesis of the compounds I is exemplified in the following Scheme 2.
- the biradical A is shown in the schemes as 2,6-naphthylene and 1,2-phenylene, respectively.
- the biradical B may be an aliphatic or non-aromatic carbocyclic or heterocyclic group or an aromatic or heteroaromatic group.
- the end group K is OH, L 1 is -O-, L 2 is -NR 5 -, and D is phenyl.
- the solid phase material, symbolised with a box is a Wang resin.
- the group M 1 preferably designates OH or O-.
- M 1 is OH or O-.
- the group L' 1 of the entity L' 1 -B-L' 2 should end up as L 1 in the compound I.
- L' 1 is, in the case where L 1 designate -O-, a hydroxyl group or a derivative thereof, preferably a hydroxyl group.
- L 1 designate -NR 5 -
- the group L' 1 is preferably the free amino group or a derivative thereof which under the reaction conditions, will liberate a free amino group.
- L' 1 is the free amino group either a primary amine, I e R 5 is hydrogen, or a secondary amine, i. e. R B is, e. g., an C 1-4 -alkyl group or designates an additional bond to B.
- groups L' 2 should remain unaffected by the reaction conditions, it preferably designates a protected hydroxy group or a protected primary or secondary amine.
- groups L' 2 are -O-P (where L 2 is -O-), where P designate a hydroxy protection groups selected from dimethoxytrityl (DMT), monomethoxytrityl (MMT), trityl, 9-(9-phenyl)xanthenyl (pixyl), tetraahydropyranyl (thp), methoxytetrahydropyranyl (mthp), trimethylsilyl (TMS), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBDMS), triethylsilyl, phenyldimethylsilyl, benzyloxycarbonyl, substituted benzyloxycarbonyl ethers such as 2-bromo benzyloxycarbonyl, tert-butyl
- a number of highly effective coupling reagents and activated forms of carboxvlic acids are know by the person skilled in the art of amide bond formation (peptide chemistry).
- Illustrative examples include the use of PyBrOP (Coste, J.; Frerot, E.; Jouin, P. and Castro, B Tetrahedron Lett 1991, 32, 1967- 1970), amino acid fluorides (Carpino, L. A., Sadat-Aalaee, D , Chao, H. G. and DeSelms, R. H. J. Am. Chem. Soc.) and HATU (Carpino, L. A. J. Am Chem Soc., 1993, 115, 4397-4398, Angell, Y. M., Garcia-Echeverria, C. and Rich, D. H. Tetrahedron Lett 1994, 35, 5981-5984, and Angell, Y. M.
- M 2 may designate OH, O-. halogen such as fluoro or chloro, or the remainder of an active ester.
- the conditions for cleaving the compound from the solid phase material is described below in connection with the examples of solid phase materials.
- the cleavage step may, where applicable include deprotection of one or more protected functional groups. It should be understood that deprotection may be performed before cleavage or after cleavage of the compound from the solid phase material. Furthermore, in an interesting instance, deprotection is performed
- any of the groups in question e. g. any or all of A, B, and D
- such chemical functionalities may be protected. Protection of the starting materials may be performed, or protection may be performed prior to the potentially harmful reaction in a separate reaction step or protection may be included in the reaction step. Protection of chemical functionalities may also become relevant in the cases where the unprotected variant of the compound in question is difficult or virtually impossible to purify.
- protecting groups were used according to state-in-the-art procedures such as those described by Greene, T. W. and Wuts, P. G.M. (Protecting Groups in Organic Synthesis).
- Preferred protecting groups are the protecting groups frequently used in solid-phase syntheses, peptide synthesis (see e. g . Steward, J. M. & Young, J. D. , Solid Phase Peptide Synthesis, Pierce Chemical Company (1984) or Robert C. Sheppard E. Atherton, Solid-Phase Peptide Synthesis, IRL Press, 1989), ohgonucleotide synthesis (see e. g. M.J.
- Protection groups are especially relevant for the amino groups, hydroxy and mercapto groups, and carboxy groups in that they may directly interfere with the reactions performed in the steps (B) and (C).
- protection groups among numerous are well know to the person skilled in the art, may not just be desirable but also necessary in order to suppress side product formation.
- Possible protection groups comprise, but is not limited to, the amino protection groups such as Fmoc (fluorenylmethoxycarbonyl), BOC (ter(-butyloxycarbonyl), trifluoroacetyl, allyloxycarbonyl (alloc, AOC), benzyloxycarbonyl (Z, Cbz) or substitued benzyloxycarbonyls such as 2-chloro benzyloxycarbonyl ((2-C1Z), DDE (Bloomberg, G B , et al , Tetrahedron Lett.
- amino protection groups such as Fmoc (fluorenylmethoxycarbonyl), BOC (ter(-butyloxycarbonyl), trifluoroacetyl, allyloxycarbonyl (alloc, AOC), benzyloxycarbonyl (Z, Cbz) or substitued benzyloxycarbonyls such as 2-chloro benzyloxycarbonyl ((2-C1Z),
- the compounds of the invention may be prepared by any well known methods or coupling reactions for the preparation of amide and ester bonds.
- Such coupling reactions for establishing amide bonds, as well as ester bonds, between an compound fragment immobilised to a solid phase material and a second chemical species are known for the person skilled in the art of solid phase synthesis.
- An example is the well-established Merrifield solid phase synthesis methodology (e.g Barany, G. , and Merrifield, R. B. in The Peptides, Vol. 2, Academic Press, New York, 1979, pp 1-284).
- solid phase material is intended to comprise solid phase materials know in the art.
- suitable solid phase materials are based on polystyrene cross-linked with 0.2-2% divinylbenzene and functionahsed as described in the literature to yield resin of the so-called "Wang-type” (Wang, S. -S. , J. Am. Chem. Soc., 1973. 94, 1328- 1333) a para-alkoxybenzyl alcohol resin which yields the free acid upon treatment and cleavage with trifluoroacetic acid/dichloromethane (1: 1, v/v) for 30 minutes at room temperature or a resin of the so-called "Rink-type” (Rink, H.
- the resins can be based on polystyrene cross-linked with 0.2-2% divinylbenzene and grafted with polyethyleneglycol (PEG) to yield the so-called "TentaGel resin” which have better and more uniform swelling characteristics in polar solvents that the parent polystyrene resins (Bayer, E. Angew. Chem. Int Ed Engl., 1991, 30, 113- 129).
- Resins of similar characteristics given from PEG-modified are commercial available with many different functionalities and are sold under trade names such as ArgoGel, PEGA resin or PEG-PS from various different vendors (e.g. Argonaut Inc., Peptide Laboratories, NovaBiochem, etc.).
- the compound 1 may after cleavage from the solid phase material undergo a further reaction step (E) for the formation of another compound of the general formula I.
- the second one is based on the use of anion exchange resins to block off one of the carboxylic acid groups while the other undergoes esterification (Blankemeyer-Menge, B. , Nimtz, M. and Frank, R. Tetrahedron Lett. 1990, 57, 1701- 1704).
- a third possible route it the selective deesterification of dicarboxylic acid diesters.
- a further possibility is using phase transfer chemistry (Friednch-Bochnitschek S. , J. Org. Chem. 54, 1989, 751-756).
- the present invention further provides a method for the preparation of a multidimensional array, ⁇ A ⁇ - ⁇ B ⁇ - ⁇ D ⁇ , i. e. a combinatorial library, of compounds consisting of at least four compounds each having the general formula I
- the total number of compound is depending on the number of fragments, i. e.
- the multi-dimentional array comprises at least four compound the product m*n*o must be at least 4.
- the combination where one of m, n, and o is four and the other two numbers each are one is possible within the method of the present invention, it is preferred that at least two of the numbers, preferably all three, are at least two, so that the highest degree of diversity of the combinatorial library is obtained.
- the combinatorial library comprises in the range of 6-200 different compound, more preferably 6- 100 different compounds, and in particular 8-64 different compounds.
- the preparation of a multi-dimensional array/library of compound follows the same principles as for the preparation of single compounds, and, thus, the synthetic scheme comprises the following steps (described for the case where the split-mix synthesis is used):
- immobilised moieties are synthesised individually, thus, each solid phase particle or entity, comprises only one type of moiety. After this step the solid phase material is pooled and split into n (see below) portions ready for the step (B). It should be understood that larger amounts of the immobilised moieties may be prepared leaving material for later experiments.
- pooling before cleavage may be advantageous seen from an economical and handling point of view. However, in the case where an analysis of the prepared library is to be performed, it is (of course) advantageous to operate with a relatively low number of compounds.
- the array of m*n*o compound may actually be present in o batches each containing m*n compound. These compound may then be pooled, e g before the actual screening is conducted. Alternatively, each of the batches may be screened individually.
- library formats could be as single compounds i.e. one vial would be containing one single compound, small mixtures of lsomeric compounds where stereoisomer would be included in the form of enantiomers, diastereomers, geometrical or positional isomers, as mixtures of typically 10- 100 compounds per vial to allow fast deconvolution down to the active substance, or as large mixtures of more than 100 compounds per vial to allow for rapid screening of vast combinatorial libraries.
- Screening are performed in assay formats usual for the high throughput mode, typically using 96 well format, 384 well format or other microplate formats compatible with automation in the search of enzyme inhibitors, receptor agonist, partial agonists, as well as neutral antagonists and negative antagonists (inverse agonists).
- biological activity of the compound I prepared according to the present invention will be demonstrated.
- biological activity within one of the following fields can be shown:
- central nervous system depressants such as sedative-hypnotics, anticonvulsants neuroleptics and anxiolytic agents, drugs to treat neuromuscular disorders such as
- antiperkinsonism agents or skeletal muscle relaxants analgesics, central nervous system stimulants, local anesthetics, cholinergic agonists, acetylcholinesterase inhibitors or cholinergic antagonists, adrenergic drugs, cardiac agents such as cardiac glycoside analogs, antiangmals, and antiarrhythmic drugs, anticoagulants, coagulants, and plasma extenders, diuretics, antiallergic and antiulcer drugs, antilipidemic drugs, nonsteroidal anti-inflammatory drugs, drugs affecting sugar metabolism, antimycobacterial agents, antibiotics or antimicrobial agents antifungal agents, antiseptics or disinfectants, as hormone antagonists, antineoplastic agents for cancer chemotherapy or photochemotherapy, antiviral agents or as a potential drugs against HIV-infections and AIDS.
- a further aspect of the invention is to provide novel compounds for the use as a medicament, and to provide the use of novel compounds for the manufacture of a medicament for one or more of the above mentioned.
- a still further aspect is to provide novel compound for the for the use in crop protection.
- FIG. 3 illustrates various examples of biradicals B. The meanings of the symbols are defined above.
- Benzophenone-2,2'-dicarboxylic acid monoallyl ester To a solution of 1.08 g (4 mmol) Benzophenone-2,2'-dicarboxylic acid In 90 ml DMF was added 0.16 g (0.5 mmol) Cs 2 CO 3 . After 30 min. 0.34 ml (0,484 g, 4 mmol) allyl bromide. The reaction mixture was stirred 24 h and 0.16 g (0.5 mmol) Cs 2 CO 3 was added. This procedure was continued until a total of 0.64 g (2 mmol) Cs 2 CO 3 was added.
- Biphenyl-2,2'-dicarboxylic acid monoallyl ester Procedure as above starting from biphenyl-2,2'-dicarboxylic acid. Colourless oil (35%). Biphenyl-2,2'-dicarboxylic acid (40%) was isolated for reuse.
- Wang resin polystyrene cross-linked with 1% divinylbenzene from NovaBiochem
- trans-N-Fmoc-4-amino-1-cyclohexanol 0.4 g (0.87-0.66 meq/g) -COOH functionalised resin was swollen in 5 ml dry dichloromethane and a solution of 0.27 g (0.8 mmol) trans-N-Fmoc-4-amino- 1-cyclohexanol in 5 ml dry dichloromethane was added. The reaction mixture was shaken 2 min and 0.237 g (0.8 mmol) MSNT and 0.254 ml (3.2 mmol) NMI was added.
- N-Fmoc-1-amino-2-propanol Procedure as above using 0.238 g (0.8 mmol) N-Fmoc-1-amino-2-propanol The two products was identified on HPLC.
- N-Fmoc-2-amino-1-butanol Procedure as above using 0.249 g (0.8 mmol) N-Fmoc-2-amino-1-butanol. The two products was identified on HPLC.
- N-Fmoc-3-amino-1-propanol Procedure as above using 0.238 g (0.8 mmol) N-Fmoc-3-amino-1-propanol. The two products was identified on HPLC.
- the resin was swollen in 7 ml dry DMF and 0.584 g (1.0 mmol) diisopropylethylaminonium salt of 4,4'-Dimethoxytrityl-oxymethyl-benzoic acid was added followed by addition of 0.520 g (1.0 mmol) PyBOP, 0.135 g (1.0 mmol) HOBT and 0.33 ml (2.0 mmol) DIPEA. After 4 days the resin was washed with 2*10 ml DMF, 2*10 ml 30% MeOH in DCM and 2*10 ml DCM for each 10 min. 4-nitro-benzoic acid.
- the 4-nitro-benzoic acid batch The 4-nitro-benzoic acid batch.
- the resin was dried and analysed on HPLC (LC-MS) and 7 of the 8 theoretically obtainable balanol analogues were identified.
- the 3-fluoro-benzoic acid batch The resin was dried and analysed on HPLC (LC-MS) and 7 of 8 theoretically obtainable balanol analogues.
- HPLC LC-MS
- 7 of 8 theoretically obtainable balanol analogues i. e. the 4,4'-Dimethoxytrityl-oxymethyl-benzoic acid batch, the 4-nitrobenzoic acid batch, the 4-methoxy-benzoic acid batch, and the 3-fluoro-benzoic acid batch, 6 7, 7, and 7 balanol-structures, respectively, were identified as distinct peaks in the LC-UV/MS analyses.
- balanol analogues containing either one of the isomeric building blocks 1-amino-propan-2-ol or 3-amino-propan- 1-ol were not observed In the analysis of the library. Several reasons can be proposed to account for this observation where precipitation of individual library members or co-elution in HPLC are very likely possibilities.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to a solid phase methodology for the preparation of a combinatorial library of structural analogues of the natural product balanol (ophiocordin, azepinostatin), which is a protein kinase C (PKC) and protein kinase A (PKA) inhibitor. The method comprises solid-phase synthesis of the analog variants of balanol whereby a high molecular diversity is introduced. The synthetic scheme is based on a retrosynthetic analysis of the native structure which revealed three main building blocks suitable as templates for modification. The dicarboxy-functional moiety can be immobilised to the polymer support either as the monoallyl ester or as the internal anhydride. The libraries produced by the method are especially suited for high throughput screening of potential drug candidates for the treatment of mammals, especially humans.
Description
BALANOL ANALOGUES FIELD OF THE INVENTION The present invention relates to a novel method for the preparation of balanol analogues using a specially developed combinatorial chemistry scheme. The scheme is also especially suited for the preparation of libraries of balanol analogues. The present invention gives access to novel classes of compounds which may have interesting and unexpected structural and functional features, and, thus, the present invention also relates to the use of the libraries for screening purposes and to the use of novel compounds as medicaments for the treatment of various diseases.
BACKGROUND OF THE INVENTION
In traditional medicinal chemistry, an average of 10,000 different compounds are synthesised and tested during the process of finding the one active component with the right pharmacological and toxicological properties (the drug). The combined experiences from a series of analytical, crystallographic, synthetic organic and computational chemistry techniques have been collected and generated a whole new field often termed "Rational Drug Design". These methods have been expected to speed up and facilitate the search for new lead compounds and drugs, but have so far not proven very effective. Today the average cost for a new drug still runs around US$ 250-350,000,000 and it takes an average of 12 years for a new drug to reach the market place.
Furthermore, in spite of obvious scientific progress during the last couple of decades, many diseases are still threatening mankind because of no or insufficient treatment. These obviously include AIDS, cardiovascular diseases and human cancers but also diseases related to neurodegenerative disorders (e. g. Alzheimer's disease), metabolic disorders (Type 2 Diabetes) and other diseases affecting not only the quantity but also the quality of life.
To facilitate this search for novel biologically active compounds, a new chemical/analytical technique has emerged. This research area is often termed combinatorial chemistry and it is one of the fastest growing research areas in modern organic chemistry. The synthesis and screening of vast and diverse libraries of small molecules might lead not only to new drugs but might also have a great importance for the discovery of novel synthetic receptors, new materials or new catalysts. Most of the reported literature in this field have been concerned with libraries consisting of small peptides and oligonucleotides because synthetic protocols for solid-phase synthesis of these molecules have been optimised for decades. However, small molecules represent a larger challenge for the synthetic organic chemist as well hold the potential for finding possible leads for the drug discovery process.
The generation of chemical diversity using combinatorial chemistry is one of the most active fields of modern organic chemistry. Initially research was focused on the generation on peptide and nucleotide libraries but more recently - due to the dubious drug-potential for finding molecules with activities in other areas such as anesthetics, central nervous system depressants such as sedative-hypnotics, anticonvulsants neuroleptics and anxiolytic agents drugs to treat neuromuscular disorders such as antiperkinsonism agents or skeletal muscle relaxants, analgesics, central nervous system stimulants, local anesthetics, cholinergic agonists, acetylcholinesterase inhibitors or cholinergic antagonists, adrenergic drugs cardiac agents such as cardiac glycosides, antianginals, and antiarrhythmic drugs, anticoagulants, coagulants, and plasma extenders, diuretics, antiallergic and antiulcer drugs, antilipidemic drugs, nonsteroidal anti-inflammatory drugs, drugs affecting sugar metabolism, antimycobacterial agents, antibiotics or antimicrobial agents, antifungal agents, as pesticides, antiseptics or disinfectants, as hormone antagonists, antineoplastic agents for cancer chemotherapy or photochemotherapy antiviral agents or as a potential drugs against HIV-infections and AIDS - the generation of non-peptidic small molecule libraries have attracted most of the attention and resources in this field.
Protein kinase C (PKC) belongs to a family of serine/threonine specific kinases which are involved in a variety of processes including signal transduction, cell proliferation and cell differentiation. Agents that inhibit PKC may have wide ranging therapeutic potential since activated PKC has been implicated in numerous disease processes. These include some widespread and severe diseases such as cancer, inflammation, cardiovascular dysfunctions, diabetic complications, asthma, central nervous system disorders and HIV infection.
Balanol is a fungal metabolite, which has attracted significant attention because it possesses high PKC inhibiting activity. Furthermore, balanol has a relatively favourable therapeutic index compared to staurosporin, which is another known PKC inhibitor. The literature contains several examples of total syntheses of balanol in solution (Lampe, J. W.; Hughes, P. F.; Bigger, C. K.; Smith, S. H.; Hu, H. J. Org. Chem. 1994, 59, 5147-5148, Lampe, J. W.; Hughes, P. F.;
Bigger, C. K.; Smith, S. H., Hu, H. J. Org. Chem. 1996, 61 , 4572-4581, Nicolaou, K. C.; Bunnage, M.E., Koide, K. J. J. Am. Chem. Soc. 1994, 1 16, 8402-8403, Adams, C. P.; Fairway, S. M.; Hardy, C.J.; Hibbs, D. E. ; Hursthouse, M. B., Morley, A.D., Sharp, B. W.; Vicker, N.; Warner, I. J. Chem. Soc. Perkin Trans. I, 1995, 2355-2362) and some analogues with improved selectivity (Lai, Y. -S.; Stamper, M. Bworg. Med. Chem. Lett. 1995, 5, 2147-2150, Lai, Y. -S.; Menaldino, D. S. , Nichols , J. B.; Jagdmann, G. E. J.; Mylott, F.; Gillespie, J.; Hall, S. E. Bworg. Med. Chem. Lett. 1995, 5, 2151-2154; Nicolaou, K. C.; Koide, K., Bunnage, M. E. Chem. Eur. J. 1995, 1 , 454-466). However, all these syntheses involve numerous synthetic steps and a level of complication in the applied chemistry that is not compatible with solid-phase organic synthesis and combinatorial chemistry
SUMMARY OF THE INVENTION
The aim of the present invention is to provide a simplified synthetic scheme for the preparation of balanol analogues using solid-phase synthesis methodologies. It is believed that a novel solid phase method for the preparation of balanol analogues may provide easier access to known analogues and also provide hitherto unknown balanol analogues. The synthetic scheme will also allow for the easy preparation of combinatorial libraries of balanol analogues.
Thus, the present invention provides a method for the preparation of balanol derivatives of the following general formula I:
K-C(=O)-A-C(=O)-L>-B-L2-C(=O)-D I wherein K-C(=O)- designates a carboxy group or a derivative thereof, each of A and B designates an organic biradical, each of L1 and L2 independently designates -NR5- or -O-, wherein each R5 independently is selected from hydrogen, optionally substituted C1-20-alkyl, optionally substituted C1-20-alkenyl, optionally substituted C1-20-alkadienyl, optionally substituted C1-20-alkatrienyl, optionally substituted aryl, and optionally substituted heteroaryl, or R3 designates an additional bond to B (whereby B becomes a triradical), and D designates optionally substituted aryl or optionally substituted heteroaryl, the method comprises the following steps:
(A) providing an optionally functional group protected moiety -C(=O)-A-C(=O)-M1 immobilised to a solid support material, wherein -C(=O)-M1 designates a carboxy group or a derivative thereof,; (B) coupling an optionally functional group protected difunctional entity L'1-B-L'2 to the -C(=O)-M1 end of the immobilised moiety -C(=O)-A-C(=O)-M1 for the formation of an optionally functional group protected immobilised fragment -C(=O)-A-C(=O)-L1-B-L'2,
(C) coupling an optionally functional group protected entity D-C(=O)-M2 wherein C(=O)-M2 designates a carboxy group or a derivative thereof, to the L'2 end of the immobilised fragment -C(=O)-A-C(=O)-L1-B-L'2 for the formation of an optionally functional group protected immobilised compound -C(=O)-A-C(=O)-L1-B-L2-C(=O)-D, the step optionally including deprotection of any protection group involved in L'2, and (D) cleaving the compound K-C(=O)-A-C(=O)-L1-B-L2-C(=O)-D from the solid support material the step optionally including deprotection of one or more functional group(s) attached to A, B, and/or D.
The present invention also provides a method for the preparation of a multi-dimensional array of compounds, {A}-{B}-{D}, consisting of at least four compounds, preferably in the range of 6-200 compounds, more preferably in the range of 6-100 compounds, in particular in the range of 8-64 compounds each having the general formula 1 as defined above, comprising the following steps:
(A) providing an array {A} of m optionally functional group protected moieties -C(=O)-A-C(=O)-M1 immobilised to a solid support material, wherein -C(=O)-M1 designates a carboxy group or a derivative thereof; (B) coupling an array {B} of n optionally functional group protected difunctional entities L'1-B-L'2 to the -C(=O)-M1 end of the immobilised moieties -C(=O)-A-C(=O)-M1 for the formation of an array {A}-{B} of m*n optionally functional group protected immobilised fragments -C(=O)-A-C(=O)-L1-B-L'2, (C) coupling an array {D} of o optionally functional group protected entities D-C(=O)-M2, wherein -C(=O)-M2 designates a carboxy group or a derivative thereof, to the L'2 end of the immobilised fragments -C(=O)-A-C(=O)-L1-B-L'2 for the formation of an array {A}-{B}-{D} of m*n*o optionally functional group protected immobilised compounds -C(=O)-A-C(=O)-L1-B-L2-C(=O)-D, the step optionally including deprotection of any protection group involved in L'2, and
(D) cleaving the array {A}-{B}-{D} of compounds K-C(=O)-A-C(=O)-L1-B-L2-C(=O)-D from the solid support material, the step optionally including deprotection of one or more functional group(s) attached to individual As, Bs, and/or Ds. Some of the novel analogues should not at first sight be expected to have any biological effects since they are structurally quite distinct from the original balanol molecule, however it is believed that such compounds may be useful as medicaments in that they are expected to have a higher specificity than balanol itself. Thus, the present invention also provides the use a compound library for screening purposes and the use of individual compound as a medicament.
DETAILED DESCRIPTION OF THE INVENTION Definitions
In the present context, the term "C1-20-alkyl" is intended to mean a linear, cyclic or branched hydrocarbon group having 1 to 20 carbon atoms, such as methyl, ethyl, propyl, iso-propyl
cyclopropyl, butyl, tert-butyl, iso-butyl, cyclobutyl, pentyl cyclopentyl, hexyl, cyclohexyl, hexadecyl, heptadecyl, octadecyl, nonadecyl. Analogously, the term "C1-6-alkyl" is intended to mean a linear, cyclic or branched hydrocarbon group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl iso-propyl, pentyl, cyclopentyl, hexyl, cyclohexyl. and the term "C1-4-alkyl" is intended to cover linear, cyclic or branched hydrocarbon groups having 1 to 4 carbon atoms, e. g. methyl, ethyl, propyl, iso-propyl, cyclopropyl, butyl, iso-butyl, tert-butyl, cyclobutyl.
Preferred examples of "C1 -6-alkyl" are methyl, ethyl, propyl, iso-propyl, butyl, tert-butyl, iso-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, in particular methyl, ethyl, propyl, iso-propyl, tertbutyl, iso-butyl and cyclohexyl. Preferred examples of "C1-4-alkyl" are methyl, ethyl, propyl, iso¬propyl, butyl, tert-butyl, and iso-butyl
Similarly, the terms "C2-20-alkenyl", "C4-20-alkadienyl", and "C6-20-alkatrienyl" are intended to mean a linear, cyclic or branched hydrocarbon group having 2 to 20, 4 to 20, and 6 to 20, carbon atoms, respectively, and comprising one, two, and three unsaturated bonds, respectively.
Examples of alkenyl groups are vinyl, allyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, heptadecaenyl. Examples of alkadienyl groups are butadienyl, pentadienyl, hexadienyl, heptadienyl, heptadecadienyl. Examples of alkatrienyl groups are hexatrienyl, heptatrienyl, octatrienyl, and heptadecatnenyl. Preferred examples of alkenyl are vinyl, allyl, butenyl, especially allyl
Similarly, the term "C2-20-alkynyl" is intended to mean a linear or branched hydrocarbon group having 2 to 20 carbon atoms and comprising a triple bond. Examples hereof are ethynyl, propynyl, butynyl, octynyl, and dodecaynyl. In the present context, i. e. in connection with the terms "alkyl", "alkenyl", "alkadienyl", "alkatnenyl", and "alkynyl", the term "optionally substituted" is intended to mean that the group in question may be substituted one or several times, preferably 1-3 times, with group(s) selected from hydroxy (which when bound to an unsaturated carbon atom may be present in the tautomeric keto form), C1-6-alkoxy (i.e. alkyl-oxy), C2-6-alkenyloxy, carboxy, oxo (forming a keto or aldehyde functionality), C1-6-alkoxycarbonyl, C1-6-alkylcarbonyl, formyl, aryl, aryloxycarbonyl aryloxy, arylcarbonyl, heteroaryl, heteroaryloxycarbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C1-6-alkyl)amino, carbamoyl, mono- and di(C1-6-alkyl)aminocarbonyl, amino- C1-6-alkyl-aminocarbonyl, mono- and di(C1-6-alkyl)amino-C1-6-alkyl-aminocarbonyl, C1-6-alkylcarbonylamino, guanidino, carbamido, C1-6-alkanoyloxy, sulphono, C1-6-alkylsulphonyloxy, nitro, sulphanyl, C1-6-alkylthio, trihalogen-C1-4-alkyl, halogen such as fluoro, chloro, bromo or lodo, where aryl and heteroaryl may be substituted as specifically describe above for "optionally substituted aryl and heteroaryl".
Preferably, the substituents are selected from hydroxy, C1-6-alkoxy, carboxy, C1-6-alkoxycarbonyl C1-6-alkylcarbonyl, formyl, aryl, aryloxycarbonyl, arylcarbonyl, heteroaryl, amino, mono- and di(C1-6-alkyl)amino, carbamoyl, mono- and di(C1-6-alkyl)aminocarbonyl, amino-C1-6-alkyl-amino- carbonyl, mono- and di(C1-6-alkyl)amino-C1-6-alkyl-aminocarbonyl, C1-6-alkylcarbonylamino, carbamido, trihalogen-C1-4-alkyl, halogen such as fluoro, chloro, bromo or lodo, where aryl and heteroaryl may be substituted 1-5 times, preferably 1-3 times, with C1-4-alkyl, C1-4-alkoxy, nitro, amino or halogen Especially preferred examples are hydroxy, C1-6-alkoxy, carboxy, aryl heteroaryl, amino, mono- and di(C1-6-alkyl)amino, and halogen such as fluoro, chloro, bromo or lodo, where aryl and heteroaryl may be substituted 1-3 times with C1-4-alkyl, C1-4-alkoxy, nitro amino or halogen.
In the present context the term "aryl" is intended to mean a fully or partially aromatic carbocyclic ring or ring system, such as phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracyl phenanthracyl, pyrenyl, benzopyrenyl, fluorenyl and xanthenyl, among which phenyl is a preferred example.
The term "heteroaryl" is intended to mean a fully or partially aromatic carbocyclic ring or ring system where one or more of the carbon atoms have been replaced with heteroatoms, e.g nitrogen (=N- or -NR5-, where R5 is selected from hydrogen and C1-4-alkyl), sulphur, and/or oxygen atoms Examples of such heteroaryl groups are oxazolyl, isoxazolyl, thiazolyl, iso-thiazolyl, pyrrolyl, lmidazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, pipendinyl, coumaryl, furyl, quinolyl, benzothiazolyl, benzotriazolyl, benzodiazolyl, benzooxozolyl, phthalazinyl, phthalanyl, triazolyl, tetrazolyl, isoquinolyl, acridinyl, carbazolyl, dibenzazepinyl, indolyl, benzopyrazolyl, phenoxazonyl. Preferred heteroaryl groups are pyridinyl, benzopyrazolyl, and lmidazolyl.
In the present context the term "non-aromatic carbocyclic and heterocyclic group" is intended to cover rings comprising carbon atoms only (carbocyclic) or carbon atoms together with
heteroatoms (heterocyclic), respectively. Heteroatoms are typically selected from nitrogen, oxygen, and sulphur. Such groups involve no unsaturated bonds or one or several unsaturated bonds, however, if present, situated in such a way that no aromatic π-electron system arises. It should be understood that the radical positions are situated directly on the ring in case of a biradical arising from such a group. Specific examples of non-aromatic carbocyclic and heterocyclic groups are oxazetane, diazetane, thiazetane, oxazolane, lmidazohdine, thiazolane, oxazilane, hexahydropyridazine, thiazilane, oxazepane, diazepane, thiazepane, oxazocane, diazocane, thiazocane, tetrahydrofuran, dihydrofuran, pyrrolidine, tetrahydrothiophen, tetrahydropyran, piperidine, tetrahydrothiopyran , oxepane, azepane, thiepane, oxocane, azocane, thiocane, cyclopropane, oxirane, azindine,
cyclopropene, azinne, cyclobutane oxetane, azetidine, thietane, 2-azetidinone 1 ,3-Iactone, pyrohdine, pyroline, pyrrole, cyclopentene, cyclopentadiene, pyrolhdione, pyrollidone cyclohexyl oxirane, dioxirane, morpholine, piperidine, 1,5-lactone, 1,5-lactam, cyclohexene cyclohexadiene, piperidione, tropane, 1,6-lactone (tropolone), 1 ,6-lactam, azepine, dihydroazepine,
tetrahydroazepine, and hexahydroazepine Especially preferred examples are oxirane, azindine, azirine, oxetane, 2-azetidinone, 1,3-lactone, pyrohdine, pyroline, pyrrole, pyrolhdone, pyrollidione, oxirane, dioxirane, morpholine, piperidine, δ-valerolactam (2-pipendone), 1 ,5-lactone, piperidione, tropolone, 1,6-lactam, azepine, dihydroazepine, tetrahydroazepine, and
hexahydroazepine Particularly preferred examples are 2-azetidinone, 1,3-lactone, pyrolhdone 1,5-lactam, 1,5-lactone, tropolone, 1,6-lactam, azepine, dihydroazepine, tetrahydroazepine, and hexahydroazepine.
In the present context, I e in connection with the terms "aryl", "heteroaryl", and "non-aromatic carbocyclic and heterocyclic group", the term "optionally substituted" is intended to mean that the group in question may be substituted one or several times, preferably 1-5 times in particular 1-3 times) with group(s) selected from hydroxy (which when present in an enol system may be represented in the tautomeric keto form), C1-6-alkyl C1-6-alkoxy, oxo (which may be represented in the tautomeric enol form), carboxy, C1-6-alkoxycarbonyl, C1-6-alkylcarbonyl, formyl, aryl, aryloxy, aryloxycarbonyl, arylcarbonyl, heteroaryl, amino, mono- and di(C1-6-alkyl)amino carbamoyl, mono- and di(C1-6-alkyl)aminocarbonyl, armno-C1-6-alkyl-aminocarbonyl, mono- and di(C1-6-alkyl)-amino-C1-6-alkyl-aminocarbonyl, C1-6-alkylcarbonylamino, guamdino, carbamido, C1-6-alkanoyloxy, sulphono, C1-6-alkyIsulphonyloxy, nitro, sulphanyl, dihalogen-C1-4-alkyl, tnhalogen-C1-4- alkyl, halogen such as fluoro, chloro, bromo or lodo, where aryl and heteroaryl representing substituents may be . Preferred examples are hydroxy, C1-6-alkyl, C1-6-alkoxy, carboxy, C1-6-alkoxycarbonyl, C1-6-alkylcarbonyl, aryl, amino, mono- and di(C1-6-alkyl)amino and halogen such as fluoro, chloro, bromo or lodo, wherein aryl and heteroaryl may be substituted as above.
In the present context the synonymous terms "organic biradical" and "biradical" are intended to have the meaning normally associated therewith. Thus, such biradicals may be derived from practically any organic molecule from which two (non-geminal and theoretical) hydrogen atoms are removed. In the present context, interesting biradicals are either linear or cyclic or comprises two or more domains selected from linear and cyclic sub-biradicals. Illustrative examples of combined biradicals comprising domains which have both linear and cyclic character are phenylene-carbonyl-phenylene, methylene-phenylene-methyleneoxy, and methylene-phenylene.
Examples of linear biradicals or domains of a combined biradical are 1-20 carbon atom alkylene chain optionally interrupted and/or terminated by one or more heteroatoms selected from O, S and NR5, and optionally substituted one or several times, preferably 1-5 times, in particular 1-5 times, with substituent(s) selected from optionally substituted C1-6-alkyl optionally substituted
C2-6-alkenyl, optionally substituted C4-8-alkadienyl, optionally substituted C6-8-alkatrienyl hydroxy oxo (thereby forming a keto or aldehyde functionality), -O-R6, formyl, -C(=O)-R6 -O-C(=O)-R6, carboxy, -C(=O)-O-R6, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted aryl, optionally substituted aryloxy, halogen such as fluoro chloro, bromo, and lodo, nitro, cyano, -N(R5)2, -NCR7)-CO-R6, carbamoyl, mono- or di(C1-6-alkyl)-aminocarbonyl, sulphanyl, optionally substituted C1-6-alkylthio, optionally substituted C1-6-alkylthio-C1-6-alkyl, (optionally substituted aryl)thio, guamdino, sulphono (-SO3H), sulphino (-SO2H), halosulphonyl, -OS(O)m-R6 where m is 2 or 3, -N(R7)S(O)m-R6 where m is 2 or 3, -S(O)m-N(R7)2 where m is 2 or 3, -S(O)m-NH(R7) where m is 2 or 3, -S(O)m-NH2 where m is 2 or 3, isocyano, isothiocyano, thiocyano, -OP(O)P(R6)q where p is 1, 2, or 3, q is 1 or 2, and p+q is 3, 4, or 5, and -N(R7)P(O)P(R6)q where p is 1, 2, or 3, q is 1 or 2, and p+q is 3, 4, or 5, wherein each R5 and each R6 independently is selected from hydrogen, optionally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-alkadienyl, optionally substituted C6-20-alkatrienyl, optionally substituted aryl, and optionally substituted heteroaryl, and each R7 is selected from hydrogen and C1-4-alkyl.
Especially preferred examples of linear biradicals or domains of a combined biradical are substituents are 1-6 carbon atom alkylene chain optionally interrupted and/or terminated by one or two heteroatoms selected from O, S, and NR6, and optionally substituted 1-3 times with substituent(s) selected from optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, hydroxy, oxo (thereby forming a keto or aldehyde functionality), -O-R6, formyl, -C(=O)-R6, -O-C(=O)-R6, carboxy, -C(=O)-O-R6, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted aryl, optionally substituted aryloxy, halogen such as fluoro chloro, bromo, and lodo, cyano, -N(R6)2, -N(R7)-CO-R6, carbamoyl, mono- or di(C1-6-alkyl)amino-carbonyl, C1-6-alkylthio, wherein each R5 and R7 independently is selected from hydrogen and C1- 4-alkyl, and each R6 independently is selected from hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2 β-alkenyl, optionally substituted aryl, and optionally substituted heteroaryl. The biradical may also consist of or comprise one or more cyclic elements, in particular 5- or 6-or 7-membered cyclic elements. Each such cyclic element may independently be saturated, unsaturated or fully or partially aromatic, it may be carbocyclic, or it may be heterocyclic by incorporating 1, 2, 3, or 4 heteroatoms, typically selected from nitrogen (=N- or -NR5-, where R5 is as defined above for the linear biradicals), oxygen or sulphur. In the case of several cyclic elements being present, these may be connected through single or double bonds, or they may be fused, or combinations thereof.
Examples of cyclic biradicals are biradicals of optionally substituted aryl groups and optionally substituted heteroaryl groups as well as biradicals of optionally substituted non-aromatic carbocyclic and heterocyclic groups.
As it will be evident from the general formula I and the definitions associated therewith, there may be one or several asymmetric carbon atoms present in the compound I depending on the nature of the biradicals and the possible substituents, cf below. The compounds prepared according to the method of the invention, as well as the compound I per se, are intended to include all stereoisomers arising from the presence of any and all isomers of the individual moieties as well as mixtures thereof, including racemic mixtures.
It should furthermore be understood that the compounds of the general formula I include possible salts thereof, of which pharmaceutically acceptable salts are especially relevant. Salts include acid addition salts and basic salts. Examples hereof are hydrochloride salts, sodium salts, calcium salts, potassium salts, etc., Pharmaceutically acceptable salts are, e.g., those described in Remington's Pharmaceutical Sciences, 17. Ed. Alfonso R.Gennaro (Ed ), Mack Publishing Company, Easton, PA, U.S.A., 1985. Furthermore, final products may also be present in hydrate form.
Construction of the compounds of the general formula I
The rationale for the method according to invention is illustrated in Scheme 1, where a retrosynthetic analysis of balanol lead to the identification of three main building blocks or synthons which are mono-protected aromatic diacids, aminoalcohols and benzoic acid
derivatives, respectively.
Thus, with reference Scheme 1, a number of modification are possible and also realistic within the scope of the present invention . For example, the balanol molecule comprises one amide bond and one ester bond, corresponding to -L2-C(=O)- and -C(=O)-L1-, respectively However, the analogues which are possible within the present invention may comprise two amide bond or two ester bonds, or the bonds may be interchanged, so that the ester bond corresponds to -L2-C(=O)and the amide bond corresponds to -C(=O)-L1-. It is furthermore believed that the benzoic acid building block may be represented by any aromatic and heteroaromatic carboxylic acid, and that the diacid may be any other dicarboxylic acid of linear, cyclic, non-aromatic or aromatic origin .
The moiety K-C(=O)- in the general formula I designates a carboxylic acid (K=OH) or a derivative thereof It should be understood that any of the carboxylic acid derivatives known in the art are possible within the definition of the present invention. However, since the moiety -C(=O)-K arises when cleaving the compound I from a solid phase resin (when the compound I is prepared according to the present invention), the moiety is typically in the free acid form
(-COOH, K=OH) or in the carboxylate form (-COO , K=O-), where the counter ion is selected from alkali metals, such as sodium and potassium, alkaline earth metals, such as calcium, and aminonium ions (N(R)2R'), or is derivatised as the amide (-CONH2, -CONHR, -CONRR', K= NH2, NHR, NRR', respectively), the hydroxylamide (-CON(OH)H, K=N(OH)H), the hydrazide (-CONHNH2, CONHNHR'", K= NHNH2, NHNHR'", respectively) or the ester (-COOR", K=R"), where each of R, R', R", and R'" independently designates optionally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-alkadienyl, optionally substituted C6 -20-alkatrienyl, optionally substituted aryl, or optionally substituted heteroaryl. Furthermore, the C-terminal carboxylic acid may be reduced to the corresponding the corresponding aldehyde (K=H) in the cleavage step Preferably, K designates OH, O , OR", NH2, NHR, or NRR', in particular OH, methoxy, or NH2, where R and R' are selected from C1-6-alkyl and benzyl, and R" is selected from C1-6-alkyl, C2-6-alkenyl, phenyl, and benzyl.
With respect to the biradical A, this may be an aliphatic biradical of the formula
-(CR3R4)n-
(i. e. an alkylene chain with no interrupting or terminating heteroatoms)
wherein n is 1-20, preferably 1-12, in particular 2-8, and where each of R3 and R4 independently is selected from hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C4-8-alkadienyl optionally substituted C6-8-alkatrienyl, hydroxy, oxo (thereby forming a keto or aldehyde functionality), -O-R6, formyl, -C(=O)-R6, -O-C(=O)-R6, carboxy, -C(=O)-O-R6, optionally substituted heteroaryl,
optionally substituted heteroaryloxy, optionally substituted aryl, optionally substituted aryloxy , halogen such as fluoro, chloro, bromo, and lodo, nitro, cyano -N(R5)2, -N(R7)-CO-R6, carbamoyl mono- or di(C1-6-alkyl)aminocarbonyl, sulphanyl, optionally substituted C1-6-alkylthio, optionally substituted C1-6-alkylthio-C1-6-alkyl, (optionally substituted aryl)thio, guanidino, sulphono (-SO3H), sulphino (-SO2H), halosulphonyl, -OS(O)m-R6 where m is 2 or 3, -N(R7)S(O)m-R6 wherein is 2 or 3, -S(O)m-N(R7)2 where m is 2 or 3, -S(O)m-NH(R7) where m is 2 or 3, -S(O)m-NH2 wherein is 2 or 3, isocyano, isothiocyano, thiocyano, -OP(O)P(R6)q where p is 1, 2, or 3, q is 1 or 2 and p+q is 3, 4, or 5, and -N(R7)P(O)p(R6)q where p is 1, 2, or 3, q is 1 or 2, and p+q is 3 4, or 5, wherein each R5 and each R6 independently is selected from hydrogen, optionally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-alkadienyl, optionally substituted C6-20-alkatrienyl, optionally substituted aryl, and optionally substituted heteroaryl, and each R7 is selected from hydrogen and C1-4-alkyl, where at the most 5, preferably at the most 3 of the substituents R3 and R4 are different from hydrogen. The substituents R3 and R4 are preferably independently selected from optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, hydroxy, oxo (thereby forming a keto or aldehyde functionality), -O-R6, formyl, -C(=O)-R6, -O-C(=O)-R6, carboxy, -C(=O)-O-R6, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted aryl, optionally substituted aryloxy, halogen such as fluoro, chloro, bromo, and lodo, cyano, -N(R5)s, -N(R7)-CO-R6, carbamoyl, mono- or di(C1-6-alkyl)aminocarbonyl, C1-6-alkylthio, wherein each R5 and R7 independently is selected from hydrogen and C1-4-alkyl, and each R6 independently is selected from hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted aryl, and optionally substituted heteroaryl Alternatively, the biradical A, illustrated as the fragment -C(=O)-A-C(=O)-, could be derived from an aliphatic or aromatic dicarbonyl functionahsed moiety, e g , as illustrated in Figure 1 and 2, wherein X is selected from the group consisting of >NR5, >NH, -O-, -S-, -Se-, -Te-, -CR'R2- >C=O, >C=S, and Y1, Y2, R1, and R2 each independently designate substituents as defined as optional substituent for aryl and heteroaryl (see above), or Y1 together with Y2 may form a biradical which together with the atoms located between these substituents, form(s) a 4-, 5-, 6-, 7- or 8-membered ring which may be an optionally substituted non-aromatic carbocyclic or
heteroaromatic ring or an optionally substituted aromatic or heteroaromatic rings, and each Z1 and Z2 independently designates =N-, =N+R5-, Preferred examples of the biradical A are biradicals either comprising or consisting of cyclic biradicals of the following radicals phenyl, naphthyl, anthracyl, pyrenyl, benzopyrenyl, phenoxazonyl, N8-phenoxazonyl, quinolyl, benzophenazinyl, ethidium and fluorenyl Especially preferred examples are naphthyl, benzopyrenyl, phenoxazonyl, N8-phenoxazonyl, quinolyl benzophenazinyl, ethidium and fluorenyl, and/or comprising or consisting of linear biradicals of
the formula -(CR3R4)n-, where each of R3 and R4 independently are selected from optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl hydroxy oxo (thereby forming a keto or aldehyde functionality), -O-R6, formyl, -C(=O)-R6, -O-C(=O)-R6, carboxy, -C(=O)-O-R6, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted aryl, optionally substituted aryloxy, halogen such as fluoro, chloro, bromo and lodo, cyano -N(R5)2, -N(R7)-CO-R6, carbamoyl, mono- or di(C1-6-alkyl)aminocarbonyl, C1-6-alkylthio, sulphono (-SO3H), sulphino (-SO2H), wherein each R5 and R7 independently is selected from hydrogen and C1-4-alkyl, and each R6 independently is selected from hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted aryl, and optionally substituted heteroaryl.
These aromatic and heteroaromatic biradicals, A, may be substituted with one or more groups selected from the same groups as defined above as substituents for the aryl and heteroaryl groups.
With respect to the carbonyl groups neighbouring A in formula I, it should be understood that these carbonyl groups may be an integral part of a starting material for the preparation of the compound I or libraries of the compound I. Thus, in most cases, it is advantageous to use, as a starting material, a cyclic entity carrying two carboxylic acid groups, one of these groups optionally in protected form, and the other group in the free acid form or in activated form, or alternatively the two carboxy groups in internal anhydride form. In this way, A may easily be linked to the solid phase material.
Illustrative examples of dicarboxylic acid functional compounds, which after incorporation into the compound 1 will represent the fragment -C(=O)-A-C(=O)-, are:
Aromatic and heteroaromatic
2,2'-biquinoline-4,4'-dicarboxylic acid, 5-nitro-isophthalic acid, 2-amino-terephthalic acid, 2-bromo-terephthalic acid, 2-nitro-terephthalic acid, 3,6-dichloro-phthalic acid anhydride, 4,5-dichloro-phthalic acid anhydride, 3-nitro-phthalic acid anhydride, 4-nitro-phthalic acid anhydride, homophthalic acid, 4,4'-biphenyl-dicarboxylic acid, 2,2 -biphenyl-dicarboxylic acid, 2,3-naphthalene-dicarboxylic acid, 2,6-naphthalene-dicarboxylic acid, 1,8-naphthalene-dicarboxylic acid anhydride, 3-nitro-1,8-naphthalene-dicarboxylic acid anhydride, 1,2-phenylendioxy-diacetic acid, embonic acid, 5,5'-dithiobis-(2-nitrobenzoic acid) (3,3'-6), 2,2'-dithiobenzoic acid, glutamic acic-5-(3-carboxy-4-nitro-anilide), ahzarin-3-methyliminodiacetic acid, 1,4-phenylene-diacetic acid, 2,4'-benzophenone-dicarboxylic acid, 2 4 -benzophenyl-dicarboxylic acid chehdamic acid, 2,3-pyridine-dicarboxylic acid, 2,4-pyridine-dicarboxylic acid, 2,5-pyridine-dicarboxylic acid, 2,6-pyridine-dicarboxylic acid, 3,4-pyridine-dicarboxylic acid, 3,5-pyridine-dicarboxylic acid, 4,5-pyridine-dicarboxylic acid, imidazole-4,5-dicarboxylic acid, 3,4,5,6-tetra
chloro-phthalic acid, 2-amino-4,6-pyrimidine-dicarboxylic acid 9,10-anthracene-dicarboxylic acid, 1,4-dihydroxy-naphthalene-2,3-dicarboxylic acid, benzimidazol-5,6-dicarboxylic acid benzo phenone-4,4'-dicarboxylic acid, 4-methoxy-phthalic acid, naphtidine-3,3'-dicarboxylic acid, naphthalene-1,2-dicarboxylic acid, naphthalene- 1 3-dicarboxylic acid, naphthalene- 1 4-dicarboxylic acid, naphthalene-1,5-dicarboxylic acid, naphthalene- 1 6-dicarboxylic acid
naphthalene- 1 ,7-dicarboxylic acid, naphthalene- 1 8-dicarboxylic acid, naphthalene-2,3-dicarboxylic acid, naphthalene-2,4-dicarboxylic acid, naphthalene-2,5-dicarboxylic acid, naphthalene-2,7-dicarboxylic acid, naphthalene-2,8-dicarboxylic acid, pyrimidine-4,6-dicarboxylic acid, pyrrazole-3,6-dicarboxylic acid, and 1, 10-phenanthroline-5,6-dicarboxylic acid, especially preferred examples are phthalic acid, isophthalic acid, terphthalic acid, 5-nitro-isophthalic acid 2,6-naphthalene dicarboxylic acid, 1,2-naphthalene dicarboxylic acid, 2,3-naphthalene dicarboxylic acid, biphenyl-4,4'-dicarboxylic acid, biphenyl-2,4'-dicarboxylic acid, 4-methoxybiphenyl-2,4'-dicarboxylic acid, 2,2'-benzophenonedicarboxylic acid, 3,3'-benzophenonedicarboxylic acid, 4,4 -benzophenonedicarboxylic acid, Benzophenone-2 4'-dicarboxylic acid, 2-methoxy-benzophenone-2'-5-dicarboxylic acid, 2-methoxy-benzophenone-4'-5-dicarboxylic acid 6,2',6'-trihydroxy-2,4'-dicarboxy-bisphenylmethane, 1, 1-(6',2 ',6'-trihydroxy-2',4"-dicarboxydiphenyl)-ethene, 6,2',6'-trihydroxybenzophenone-2,4'-dicarboxylic acid, 6 2',6'-trimethoxybenzophenone-2,4'-dicarboxylic acid, 2-carboxamido-6,2',6 -trihydroxybenzophenone-4'-carboxylic acid, 2-carboxyethyl-6,2',6'-tnhydroxybenzophenone-4'-carboxylic acid, 2-carboxymethyl-6,2',6 -trihydroxybenzophenone-4'-carboxylic acid, 6,2',6'-trifluorobenzophenone-2,4'-dicarboxylic acid, 2 ,6'-dimethoxy-6-hydroxybenzophenone-2,4'-dicarboxylic acid. and Linear and non-aromatic :
oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, undecanedioic acid, dodecanedioic acid, tetradecanedioic acid, hexadecanedioic acid docosanedioic acid, trans, trans-muconic acid, methylmaleic acid, methylmaleic acid anhydride, (+)- and (-)-camphonc acid, 1,3-acetone dicarboxylic acid, N-(acetamido)-iminodiacetic acid, L-aspartic acid, S-carboxymethyl-L-cysteine, 2,2'-(ethylendithio)-diacetic acid, malic acid (+ and -), D-penicillamme, phenylsuccinic acid, N-(phosphonomethyl)-lminodiacetic acid, tetrahydrofolic acid, (+ or -) O,O'-dibenzyI-2-tartaric acid, (3-thienyl)-malonic acid, N-phtaloyl-1-glutamic acid, diphenyl maleic anhydride, cis- 1,2,3,6-tetrahydrophthalic acid 3,4,5,6-tetrahydrophthalic acid, pyrazine-2,3-dicarboxylic acid, ticarcillin, chelidonic acid, glycine cresol red, cyclopropane-1, 1'-dicarboxylic acid, cyclobutane-1,1'-dicarboxylic acid, 1-cyclopentene-1,2-dicarboxylic acid anhydride, 1, 1'-azobis-(cyclohexane-carboxylic acid), cyclopropane- 1,2-dicarboxylic acid, (cis+trans)- 1,4-cyclohexandicarboxylic acid, pyrazine-2,5-dicarboxylic acid piperidine-2,6-dicarboxylic acid, piperidine-3,3-dicarboxylic acid, pyrroline-N-oxide-5,5-dicarboxylic acid, γ-pyrone-2,6-dicarboxylic acid and piperazine-2,6-dicarboxylic acid.
With respect to the biradical B, it is believed that this can be an aliphatic biradical of the formula
-(CR3R4)n- where R3, R4 and n are as defined above for A.
Alternatively, B could be derived from an aliphatic or aromatic amino alcohol, e.g., as illustrated in Figure 3, wherein X is selected from the group consisting of >NR6, >NH, -O-, -S-, -Se-, -Te-, -CR1R2-, >C=O, >C=S, and Y1, Y2, R1, and R2 each independently designates substituents as defined as optional substituent for aryl and heteroaryl (see above), or Y1 together with Y2 may form a biradical which together with the atoms located between these substituents, form(s) a 4- 5-, 6-, 7- or 8-membered ring which may be an optionally substituted non-aromatic carbocyclic or heteroaromatic ring or an optionally substituted aromatic or heteroaromatic rings, and each Z1 and Z2 independently designates =N-, =N+R5-;
Preferred examples of the biradical B are, e g , biradicals of the following non-aromatic carbocyclic compounds cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cycloheptane and cyclooctane, the following aromatic or non-aromatic heterocyclic compounds epoxides, aziridines, thioepoxides, oxazetane, diazetane, thiazetane, oxazolane, lmidazolidine, thiazolane, oxazilane, hexahydropyridazine, thiazilane, oxazepane, diazepane, thiazepane, oxazocane, diazocane, thiazocane, tetrahydrofuran, dihydrofuran, pyrrolidine, tetrahydrothiophen, tetrahydropyran, piperidine, tetrahydrothiopyran, oxepane azepane, thiepane, oxocane, azocane, thiocane, cyclopropane, oxirane aziridine, cyclopropene, azirine cyclobutane, oxetane, azetidine, thietane, 2-azetidinone, 1,3-lactone, pyrrolidine pyrroline pyrrole, pyrrolidione, pyrrolidone, oxirane, dioxirane, morpholine, piperidine, 1 ,5-lactone, 1,5-lactam, cyclohexene, cyclohexadiene, piperidione, tropane, 1,6-lactone (tropolone), 1,6-lactam azepine, dihydroazepine, tetrahydroazepine, and hexahydroazepine As appears from the above, each of L1 and L2 independently designates -NR5- or -O-, wherein each R5 independently is selected from hydrogen, optionally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-alkadienyl optionally substituted C6-20- alkatrienyl, optionally substituted aryl, and optionally substituted heteroaryl, or R6 designates an additional bond to B (whereby B becomes a triradical) Preferably R5 designates hydrogen, C1-4-alkyl or an additional bond to B In particular, one of L1 and L2 is -O- and the other is -NR5-, where R5 designates hydrogen, C1-4-alkyl or an additional bond to B.
Thus, interesting and highly relevant starting materials for the preparation of the compounds I are 1-amino-ω-hydroxy-(optionally substituted)-C1-6-alkylene, where C1-6-alkylene is the biradical of the radicals defined for C1-6-alkyl and optional substituents are as defined for "alkyl". When the aminoalcohol is selected from the group of non-aromatic carbocyclic compounds or heterocyclic compounds the hydroxy- and amino-function can be positioned 1 ,2-, 1,3-, 1 ,4- or 1,5-, where applicable, to each other as well as the stereochemical environment of the amino and alcohol groups can be positioned either in a cis-configuration where the two substituents are on the same side of the ring or could be positioned trans-configuration where the two substituents are on the different side of the ring system. Likewise, different enantiomers (mirror images) and diastereoisomers can exist as an inherent result of the chirahty in such substituted non-aromatic carbocyclic compounds or heterocyclic compounds. Thus, especially preferred examples are aminoalcohols derived from non-aromatic carbocyclic and heterocyclic compounds where the hydroxy and amino function are positioned 1,2 or 1,3 relative to each other, especially 1 ,2 to each other.
Specific examples of aminoalcohols derived from non-aromatic carbocyclic compounds are 2-aminoethanol, 1-amino-2-propanol, 3-amino- 1-propanol, 2-amino- 1-propanol, 2-amino-2-methyl- 1-propanol, 1-amino-2-methyl-2-propanol, 3-amino-2-methyl- 1-propanol, 2-amino-1-butanol, 1 -amino-2-butanol, 3-amino-3-butanol, 3-amino- 1-butanol, 4-amino-2-butanol, cis-2-amino- 1-cyclobutanol, trans-2-amino- 1-cyclobutanol, 5-amino-1-pentanol, 2-amino- 1 -pentanol, 3-amino-2-pentanol, 2-amino-3-pentanol, 1-amino-2-pentanol, cis-2-amino- 1-cyclopentanol, trans-2-amino-1-cyclopentanol, 6-amino- 1-hexanol, trans-4-amino- 1-cyclohexanol, cis-4-amino- 1-cyclohexanol, trans-2-amino- 1-cyclohexanol, cis-2-amino- 1-cyclohexanol, cis-2-amino- 1-cyclohexanol, cis-2-amino-4-methyl- 1-cyclohexanol, cis-2-amino-5-methyl- 1-cyclohexanol, trans-2-amino- 1-cycloheptanol, cis-2-amino-1-cycloheptanol, trans-2-amino- 1-cyclooctanol, cis-2-amino- 1-cyclooctanol
Specific examples of aminoalcohols derived from heterocyclic compounds are cis-4-amino-3-hydroxy-pyrolidine, trans-4-amino-3- hydroxy-pyrrolidine, cis-4-amino-3-hydroxy-tetrahydrofuran, trans-4-amino-3-hydroxy- tetrahydrofuran, cis-4-amino-3-hydroxy-tetrahydrothiophen, trans-4-amino-3-hydroxy-tetrahydrothiophen, cis-3-amino-4-hydroxy-piperidine, trans-3-amino-4-hydroxy-piperidine, cis-4-amino-3-hydroxy-piperidine, trans-4-amino-3-hydroxy-piperidine, cis-5-amino-3-hydroxy-piperidine, trans-5-amino-3-hydroxy-pipendine, cis-4-amino-3-hydroxytetrahydro-2H-pyrane, trans-4-amino-3-hydroxy-tetrahydro-2H-pyrane, cis-4-amino-3-hydroxytetrahydro-2H-thiopyrane, trans-4-amino-3-hydroxy-tetrahydro-2H-thiopyrane, cis-5-amino-4-hydroxy-2-piperidone, trans-5-amino-4-hydroxy-2-piperidone, trans-3-amino-4-hydroxy-azepane, cis-3-amino-4-hydroxy-azepane, trans-4-amino-3-hydroxy-azepane, cis-4-amino-3-hydroxy-azepane, trans-5-amino-4-hydroxy-azepane cis-5-amino-4-hydroxy-azepane trans- 3-amino-4-
hydroxy-oxepane, cis-3-amino-4-hydroxy-oxepane trans-3-amino-4-hydroxy-azocane cis-3-amino-4-hydroxy-azocane
The fragment D-C(=O) in the formula I is obviously derived from an aromatic carboxylic acid or a derivative thereof. Thus, it is believed that a huge number of readily (and also commercially) available starting materials for the preparation of the compound I can be utilised. Furthermore, the chemistry of aromatic compound is quite developed, so the group of accessible compound may be further supplemented. Preparation of the compounds of the general formula I
The synthesis of the compounds I is exemplified in the following Scheme 2. With reference to the general formula I, the biradical A is shown in the schemes as 2,6-naphthylene and 1,2-phenylene, respectively. The biradical B may be an aliphatic or non-aromatic carbocyclic or heterocyclic group or an aromatic or heteroaromatic group. The end group K is OH, L1 is -O-, L2 is -NR5-, and D is phenyl. Furthermore, the solid phase material, symbolised with a box, is a Wang resin.
The example illustrated in Scheme 2 represents two possible embodiments of the method according to the invention. Thus, in each of the steps (A)-(D), variations are possible. In the following general guidelines for each of the steps of the method according to invention are given:
Step (A): an optionally functional group protected moiety -C(=O)-A-C(=O)-M1 immobilised to a solid support material, wherein -C(=O)-M1 designates a carboxy group or a derivative thereof, is provided.
As illustrated in Scheme 2, various possibilities for the immobilisation are comprised within the scope of the present invention. Normally, it is preferred to use the diacid in monoester form, in that use of the dicarboxylic acid may lead to side product formation due to the lack of monoselectivity in the reaction between the activated solid phase material and the diacid. Thus, it is believed, and can also be demonstrated, that used of the dicarboxylic acid in the free acid form will lead to a lower yield, such a lower yield may, however, compensate for the resources used when preparing, e.g. , the monoester.
Another example is the case where an internal anhydride of a dicarboxylic acid is used. In the cases where the dicarboxylic acid is mono-protected, the protecting group is preferably removed in order to provide the carboxy functionality in a form, C(=O)-M1, ready for coupling in step (B). Thus, the group M1 preferably designates OH or O-. The conditions for coupling the dicarboxylic acid to the solid phase material is closely connected to the choice of solid phase material and linker, and will be described further below.
Step (B): an optionally functional group protected difunctional entity L'1-B-L'2 is coupled to the -C(=O)-M1 end of the immobilised moiety -C(=O)-A-C(=O)-M1 for the formation of an optionally functional group protected immobilised fragment -C(=O)-A-C(=O)-L1-B-L'2.
First of all, the group -C(=O)-M1 should be present in a form susceptible to reaction with the entity L'1-B-L'2, thus, as described above, -C(=O)-M1 is preferably a carboxy group or a carboxylate group, or, alternatively, in reactive form, e.g. in active ester form. Preferably M1 is OH or O-. It is clear that the group L'1 of the entity L'1-B-L'2 should end up as L1 in the compound I. Thus, L'1 is, in the case where L1 designate -O-, a hydroxyl group or a derivative thereof, preferably a hydroxyl group. In the case where L1 designate -NR5-, the group L'1 is preferably the free amino group or a derivative thereof which under the reaction conditions, will liberate a free amino group. Preferably L'1 is the free amino group either a primary amine, I e R5 is hydrogen, or a secondary amine, i. e. RB is, e. g., an C1-4-alkyl group or designates an additional bond to B.
As the group L'2 should remain unaffected by the reaction conditions, it preferably designates a protected hydroxy group or a protected primary or secondary amine. Examples of groups L'2 are -O-P (where L2 is -O-), where P designate a hydroxy protection groups selected from dimethoxytrityl (DMT), monomethoxytrityl (MMT), trityl, 9-(9-phenyl)xanthenyl (pixyl), tetraahydropyranyl (thp), methoxytetrahydropyranyl (mthp), trimethylsilyl (TMS), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBDMS), triethylsilyl, phenyldimethylsilyl, benzyloxycarbonyl, substituted benzyloxycarbonyl ethers such as 2-bromo benzyloxycarbonyl, tert-butylethers, methyl ethers, acetyl, halogen substituted acetyls such as chloroacetyl and fluoroacetyl, isobuteryl, pivaloyl, benzoyl, substituted benzoyls, methoxymethyl (MOM), benzyl ethers, and substituted benzyl ethers such as 2,6-dichlorobenzyl (2,6-Cl2Bzl), and -NR6-P (where L1 is -NR5-), where P designates an amino protection groups selected from Fmoc (fluorenylmethoxycarbonyl), BOC (tert-butyloxycarbonyl), trifluoroacetyl, allyloxycarbonyl (alloc, AOC), benzyloxycarbonyl (Z, Cbz), substitued benzyloxycarbonyls such as 2-chloro benzyloxycarbonyl ((2-ClZ), DDE
(Bloomberg, G.B., et al , Tetrahedron Lett 1993 34, 4709-4712), monomethoxytrityl (MMT), dimethoxytrityl (DMT), and 9-(9-phenyl)xanthenyl (pixyl).
The coupling reaction in step (B) will often include a coupling reagent, e. g. a reagent which converts the group -C(=O)-M1 into an active derivative, e. g. an active ester or an acid halide. A number of highly effective coupling reagents and activated forms of carboxvlic acids are know by the person skilled in the art of amide bond formation (peptide chemistry). Illustrative examples include the use of PyBrOP (Coste, J.; Frerot, E.; Jouin, P. and Castro, B Tetrahedron Lett 1991, 32, 1967- 1970), amino acid fluorides (Carpino, L. A., Sadat-Aalaee, D , Chao, H. G. and DeSelms, R. H. J. Am. Chem. Soc.) and HATU (Carpino, L. A. J. Am Chem Soc., 1993, 115, 4397-4398, Angell, Y. M., Garcia-Echeverria, C. and Rich, D. H. Tetrahedron Lett 1994, 35, 5981-5984, and Angell, Y. M. , Thomas, T. L. , Flenkte, G. R. and Rich, D. R. J. Am Chem. Soc 1995, 117, 7279-7280), PyBOP (Frerot, E., et al. , Tetrahedron, 1991 , 47(2), pp 259-270), and CFs-NOz-PyBOP (Wijkmans, J. C. H. M. , et al, Tetrahedron Lett, 1995, 36(26), pp 4643-4646). A coupling reagent will be equally applicable for the formation of an amide bond as for the formation of an ester bond.
Step (C): an optionally functional group protected entity D-C(=O)-M2, wherein C(=O)-M2 designates a carboxy group or a derivative thereof, is coupled to the L'2 end of the immobilised fragment -C(=O)-A-C(=O)-L1-B-L'2 for the formation of an optionally functional group protected immobilised compound -C(=O)-A-C(=O)-L1-B-L2-C(=O)-D, the step optionally including deprotection of any protection group involved in L'2.
As described under step (B), the group L'2 typically includes a protecting group, thus in that case, such a group should preferably be removed before coupling of the entity D-C(=O)-M2 to the immobilised fragment. With respect to the group -C(=O)-M2. it may be a carboxy group or derivative thereof. In one variant the group -C(=O)-M2 is a reactive derivative of a carboxylic acid, e g an active ester or the acid halide, e. g. the acid chloride or fluoride In another variant, the group -C(=O)-M2 is the free acid or the carboxylate thereof. In the latter case, the reaction typically involves the use of a coupling agent. Thus, M2 may designate OH, O-. halogen such as fluoro or chloro, or the remainder of an active ester.
Step (D): the compound K-C(=O)-A-C(=O)-L1-B-L2-C(=O)-D is cleaved from the solid support material, the step optionally including deprotection of one or more functional group(s) attached to A, B, and/or D. The conditions for cleaving the compound from the solid phase material is described below in connection with the examples of solid phase materials. The cleavage step may, where applicable include deprotection of one or more protected functional groups. It should be understood that deprotection may be performed before cleavage or after cleavage of the compound from the solid
phase material. Furthermore, in an interesting instance, deprotection is performed
simultaneously to cleavage of the compound from the solid phase material. The latter possibility applies when a Wang resin is used In this instance trifluoroacetic acid (TFA) is used for cleavage of the compound and deprotection of any Boc amino protecting groups.
In the present context the term "optionally functional group protected" and similar terms are intended to mean that in the case where any of the groups in question, e. g. any or all of A, B, and D, comprises a chemical functionality (or several chemical functionalities) which is/are susceptible to reaction, alteration or degradation under the reaction conditions in question or due to the lack of regioselectivity of the reagents used, such chemical functionalities may be protected. Protection of the starting materials may be performed, or protection may be performed prior to the potentially harmful reaction in a separate reaction step or protection may be included in the reaction step. Protection of chemical functionalities may also become relevant in the cases where the unprotected variant of the compound in question is difficult or virtually impossible to purify. In such cases a protection-purification-deprotection scheme may be applied. Protecting groups were used according to state-in-the-art procedures such as those described by Greene, T. W. and Wuts, P. G.M. (Protecting Groups in Organic Synthesis). Preferred protecting groups are the protecting groups frequently used in solid-phase syntheses, peptide synthesis (see e. g . Steward, J. M. & Young, J. D. , Solid Phase Peptide Synthesis, Pierce Chemical Company (1984) or Robert C. Sheppard E. Atherton, Solid-Phase Peptide Synthesis, IRL Press, 1989), ohgonucleotide synthesis (see e. g. M.J. Gait, Ohgonucleotide Synthesis, IRL Press, 1984), ohgosaccharide synthesis, organic synthesis and during synthesis of natural products Protection groups are especially relevant for the amino groups, hydroxy and mercapto groups, and carboxy groups in that they may directly interfere with the reactions performed in the steps (B) and (C). Thus, protection groups, among numerous are well know to the person skilled in the art, may not just be desirable but also necessary in order to suppress side product formation.
Possible protection groups comprise, but is not limited to, the amino protection groups such as Fmoc (fluorenylmethoxycarbonyl), BOC (ter(-butyloxycarbonyl), trifluoroacetyl, allyloxycarbonyl (alloc, AOC), benzyloxycarbonyl (Z, Cbz) or substitued benzyloxycarbonyls such as 2-chloro benzyloxycarbonyl ((2-C1Z), DDE (Bloomberg, G B , et al , Tetrahedron Lett. 1993 34, 4709-4712), monomethoxytrityl (MMT), dimethoxytrityl (DMT), and 9-(9-phenyl)xanthenyl (pixyl), hydroxy protection groups such as dimethoxytrityl (DMT), monomethoxytrityl (MMT), trityl, 9-(9-phenyl)xanthenyl (pixyl), tetraahydropyranyl (thp), methoxytetrahydropyranyl (mthp), trimethylsilyl (TMS), triisopropylsilyl (TIPS), (er(-butyldimethylsilyl (TBDMS), triethylsilyl, phenyldimethylsilyl, benzyloxycarbonyl or substituted benzyloxycarbonyl ethers such as 2-bromo benzyloxycarbonyl, (erf-butylethers, methyl ethers, acetyl or halogen substituted acetyls such as chloroacetyl or fluoroacetyl, isobutyryl, pivaloyl, benzoyl and substituted benzoyls, methoxymethyl (MOM), benzyl ethers or substituted benzyl ethers such as 2,6-dichlorobenzyl (2,6-
Cl2Bzl), carboxy protection groups such as allyl esters, methyl esters, ethvl esters 2-cvanoethylesters, trimethylsilylethylesters, benzyl esters (Obzl), 2-adamantyl esters (O-2-Ada), cyclohexyl esters (Ocllex), 1,3-oxazolines, oxazoler, 1,3-oxazohdines, amides or hydrazides, or in the form of an activated ester such as an N-hydroxysuccimmide or an symmetric or asymmetric anhydride, and mercapto protecting groups such as trityl (Trt), acetamidomethyl (acm), trimethylacetamidomethyl (Tacm), 2,4,6-trimethoxybenzyl (Tmob), tert-butylsulfenyl (S(Bu), 9-fluorenylmethyl (Fm), 3-nitro-2-pyridinesulfenyl (Npys), and 4-methylbenzyl (Meb).
Deprotection of any "optionally protected functional groups" is performed by methods known by the person skilled in the art, e. g. as described in Greene, T. W. and Wuts, P. G.M. (Protecting Groups in Organic Synthesis).
The compounds of the invention may be prepared by any well known methods or coupling reactions for the preparation of amide and ester bonds. Such coupling reactions for establishing amide bonds, as well as ester bonds, between an compound fragment immobilised to a solid phase material and a second chemical species are known for the person skilled in the art of solid phase synthesis. An example is the well-established Merrifield solid phase synthesis methodology (e.g Barany, G. , and Merrifield, R. B. in The Peptides, Vol. 2, Academic Press, New York, 1979, pp 1-284).
In the present context the term "solid phase material" is intended to comprise solid phase materials know in the art. Especially suitable solid phase materials (polymers) are based on polystyrene cross-linked with 0.2-2% divinylbenzene and functionahsed as described in the literature to yield resin of the so-called "Wang-type" (Wang, S. -S. , J. Am. Chem. Soc., 1973. 94, 1328- 1333) a para-alkoxybenzyl alcohol resin which yields the free acid upon treatment and cleavage with trifluoroacetic acid/dichloromethane (1: 1, v/v) for 30 minutes at room temperature or a resin of the so-called "Rink-type" (Rink, H. Tetrahedron Lett. , 1987.28, 3787-3790) ) a tnalkoxy-diphenyl-methylester resin which yields the acid amide upon treatment and cleavage with trifluoroacetic acid/dichloromethane (3: 7, v/v) for 60 minutes at room temperature.
Likewise, the resins can be based on polystyrene cross-linked with 0.2-2% divinylbenzene and grafted with polyethyleneglycol (PEG) to yield the so-called "TentaGel resin" which have better and more uniform swelling characteristics in polar solvents that the parent polystyrene resins (Bayer, E. Angew. Chem. Int Ed Engl., 1991, 30, 113- 129). Resins of similar characteristics given from PEG-modified are commercial available with many different functionalities and are sold under trade names such as ArgoGel, PEGA resin or PEG-PS from various different vendors (e.g. Argonaut Inc., Peptide Laboratories, NovaBiochem, etc.).
In a further embodiment of the methods of present invention, the compound 1 may after cleavage from the solid phase material undergo a further reaction step (E) for the formation of another
compound of the general formula I. This reaction step may be especially relevant yvhen modification of the group K-C(=O)- is desired due to the fact that the variability of this group is governed by the applicable method for cleavage of the compound from the resin. Preparation of monoesters of dicarboxylic acids
As the first step in the preparation of the compounds I involves the moiety -C(=O)-A-(=O)-, it is evident that a diacid HOOC-A-COOH, e. g. in the free acid monoester, or internal anhydride form may be used when providing the immobilised moiety -C(=O)-A-C(=O)-M1
In order to be able to utilise a wide range of bifunctional aromatic and heteroaromatic molecules in the synthesis of compounds I, the accessibility to synthetic routes towards, e.g., aromatic dicarboxylic acid monoesters are advantageous. Three different syntheses have been described in Tong, G. and Nielsen, J. Bworg. Med. Chem. 1996, 4, 693-698. The first method is based on the esterif ication, in particular the allylation, of the monocesium salt of a dicarboxylic acid, exemplified herein as esterification of naphthalene-2,6-dicarboxylic acid with allyl bromide (Example 3). The second one is based on the use of anion exchange resins to block off one of the carboxylic acid groups while the other undergoes esterification (Blankemeyer-Menge, B. , Nimtz, M. and Frank, R. Tetrahedron Lett. 1990, 57, 1701- 1704). A third possible route it the selective deesterification of dicarboxylic acid diesters. A further possibility is using phase transfer chemistry (Friednch-Bochnitschek S. , J. Org. Chem. 54, 1989, 751-756). Advantageous conditions for the production of the monoester with a minimum yield of the diester were an equimoiar amount of Cs2CO3 added in small portions over an extended period such as 16 h, and 2 equivalents of allyl bromide. Obtainable yields of the purified monoester are at least 30%. An alternative method based on the adsorption of the naphthalene diacid onto an anion exchange resin followed by reaction with mesithylenesulphonylmtrotriazolide (MSNT), N-methyhmidazole and allyl alcohol produces the desired monoester. The third method is based on the possibility of mono-deesterification of certain aromatic dimethyl esters. Synthesis of the mixed methyl-allyldiester followed by selective demethylation (NaCN/HMPA(hexamethylphosphoramide)) yields the corresponding monoallyl ester.
Preparation of libraries of compounds of the general formula I
The preparation of compound libraries of balanol analogues follows the same principles as described above for the preparation of single analogues. In order to ensure that a suitable amount of each of the theoretically obtainable compound were formed in a suitable amount, the split-mix synthesis method (Furka, A. ; Sebestyen, F. ; Asgedom, M. , Dibò G. Int. J. Peptide
Protein Res 1991 37, 487-493) was applied. Other method may also be applicable within the context of the present invention.
Thus, the present invention further provides a method for the preparation of a multidimensional array, {A}-{B}-{D}, i. e. a combinatorial library, of compounds consisting of at least four compounds each having the general formula I
K-C(=O)-A-C(=O)-L1-B-L2-C(=O)-D I as defined above. Such an array is constructed by combining an array {A} consisting of m compounds corresponding to the biradical -C(=O)-A-C(=O)- with an array {B} consisting of n compound corresponding to the biradical -L'-B-L2- and an array {C} consisting of o compound corresponding to the radical -C(=O)-D. The total number of compound is depending on the number of fragments, i. e. m, n, and o These numbers, m, n, and o are all positive integers, and in order for the multi-dimentional array to comprise at least four compound the product m*n*o must be at least 4. Although the combination where one of m, n, and o is four and the other two numbers each are one is possible within the method of the present invention, it is preferred that at least two of the numbers, preferably all three, are at least two, so that the highest degree of diversity of the combinatorial library is obtained. Thus, it also is preferred that the combinatorial library comprises in the range of 6-200 different compound, more preferably 6- 100 different compounds, and in particular 8-64 different compounds.
As mentioned above, the preparation of a multi-dimensional array/library of compound follows the same principles as for the preparation of single compounds, and, thus, the synthetic scheme comprises the following steps (described for the case where the split-mix synthesis is used):
Step (A) : an array {A} of m optionally functional group protected moieties -C(=O)-A-C(=O)-M1 immobilised to a solid support material, wherein -C(=O)-M1 designates a carboxy group or a derivative thereof, is provided. Following the split-mix synthesis, each of the types of
immobilised moieties are synthesised individually, thus, each solid phase particle or entity, comprises only one type of moiety. After this step the solid phase material is pooled and split into n (see below) portions ready for the step (B). It should be understood that larger amounts of the immobilised moieties may be prepared leaving material for later experiments. Step (B): an array {B} of n optionally functional group protected difunctional entities L'1-B-L'2 is coupled to the -C(=O)-M1 end of the immobilised moieties -C(=O)-A-C(=O)-M1 for the formation of an array {A}-{B} of nvn optionally functional group protected immobilised fragments -C(=O)-A-C(=O)-L1-B-L'2. Also in this step to coupling is preferably performed in n different batches where the reacted material is pooled and split for the next coupling step, i. e. step (C).
Step (C): an array {D} of o optionally functional group protected entities D-C(=O)-M2 wherein -C(=O)-M2 designates a carboxy group or a derivative thereof, is coupled to the L'2 end of the immobilised fragments -C(=O)-A-C(=O)-L1-B-L'2 for the formation of an array {A}-{B}-{D} of m*n*o optionally functional group protected immobilised compounds -C(=O)-A-C(=O)-L1-B-L2-C(=O)-D, the step optionally including deprotection of any protection group involved in L'2. Also in this step the coupling is preferably performed in o different batches. The reacted material need not necessarily to be pooled before cleavage in step (D). Step (D): cleaving the array {A}-{B}-{D} of compounds K-C(=O)-A-C(=O)-L1-B-L2-C(=O)-D from the solid support material, the step optionally including deprotection of one or more functional group(s) attached to individual As, Bs, and/or Ds. It should be understood that the o different batches from step (C) may be cleaved individually or the batches may be pooled before cleavage. Pooling before cleavage may be advantageous seen from an economical and handling point of view. However, in the case where an analysis of the prepared library is to be performed, it is (of course) advantageous to operate with a relatively low number of compounds. Thus, the array of m*n*o compound may actually be present in o batches each containing m*n compound. These compound may then be pooled, e g before the actual screening is conducted. Alternatively, each of the batches may be screened individually. In a third and most interesting alternative the library consisting of the combined batches (or a number of these) containing (up to) m*n*o compound is screened, and in the case where biological activity is identified, each of the o batches are screened individually thereby pointing back to one specific moiety D as biologically interesting. The principles of screening are discussed in the following. Method of screening
Screening of combinatorial libraries may be performed in any of the ways generally used by scientists and technicians skilled in the art. These include but is not limited to screening of individual compounds, by deconvolution of libraries containing mixtures by positional scanning of libraries of mixtures or by screening sub-libraries in an index library mode. Therefore, library formats could be as single compounds i.e. one vial would be containing one single compound, small mixtures of lsomeric compounds where stereoisomer would be included in the form of enantiomers, diastereomers, geometrical or positional isomers, as mixtures of typically 10- 100 compounds per vial to allow fast deconvolution down to the active substance, or as large mixtures of more than 100 compounds per vial to allow for rapid screening of vast combinatorial libraries. Screening are performed in assay formats usual for the high throughput mode, typically using 96 well format, 384 well format or other microplate formats compatible with automation in the search of enzyme inhibitors, receptor agonist, partial agonists, as well as neutral antagonists and negative antagonists (inverse agonists).
By such screening methods it is envisaged that biological activity of the compound I prepared according to the present invention will be demonstrated. Thus it is believed that biological activity within one of the following fields can be shown:
(a) Biological effects interesting in the treatment of mammals such as human beings
anesthetics, central nervous system depressants such as sedative-hypnotics, anticonvulsants neuroleptics and anxiolytic agents, drugs to treat neuromuscular disorders such as
antiperkinsonism agents or skeletal muscle relaxants, analgesics, central nervous system stimulants, local anesthetics, cholinergic agonists, acetylcholinesterase inhibitors or cholinergic antagonists, adrenergic drugs, cardiac agents such as cardiac glycoside analogs, antiangmals, and antiarrhythmic drugs, anticoagulants, coagulants, and plasma extenders, diuretics, antiallergic and antiulcer drugs, antilipidemic drugs, nonsteroidal anti-inflammatory drugs, drugs affecting sugar metabolism, antimycobacterial agents, antibiotics or antimicrobial agents antifungal agents, antiseptics or disinfectants, as hormone antagonists, antineoplastic agents for cancer chemotherapy or photochemotherapy, antiviral agents or as a potential drugs against HIV-infections and AIDS.
(b) Biological effects interesting in the field of crop protection compounds affecting sugar metabolism, antibiotics or antimicrobial agents, antifungal agents, such as pesticides, disinfectants, and hormone antagonists.
Thus, a further aspect of the invention is to provide novel compounds for the use as a medicament, and to provide the use of novel compounds for the manufacture of a medicament for one or more of the above mentioned. A still further aspect is to provide novel compound for the for the use in crop protection.
DESCRIPTION OF THE DRAWINGS Figures 1 and 2 illustrate various examples of biradicals A. The meanings of the symbols are defined above.
Figure 3 illustrates various examples of biradicals B. The meanings of the symbols are defined above.
EXAMPLES
Example 1 Procedure for the synthesis of N-Fmoc-aminoalcohols
N-Fmoc-1-amino-2-propanol. Procedure as above starting from l-amino-2-propanol. White solid (100%) Mp 120- 123°C. 1H NMR (CDCl3) d 7.8 (d, 2H, J = 6.5 Hz), 7.6 (d, 2H J = 6.5 Hz), 7.3 (m, 4H), 5.2 (m, 1H), 4.5 (d, 2H, J = 6.8), 4.2 (t, 1H, J = 6.8), 3.9 (m, 1H), 3.3-3.1 (m, 2H), 2.5 (m, 1H), 1.2 (d, 3H, J = 6.0). 13C NMR (CDCI3) d 156.0 143.8 141.2 127.6 127.0 124.9 1 19.9 67.3 66.7 48.2 47.2 20.6.
N-Fmoc-2-amino-1-butanol. Procedure as above starting from 2-amino-1-butanol. White solid (96%). Mp 127- 131°C. 1H-NMR (CDCI3) d 7.8 (d, 2H, J = 6.5 Hz), 7.6 (d, 2H. J = 6.5 Hz), 7.4 (m, 4H), 4.9 (m, 1H), 4.5 (d, 2H, J = 7 Hz), 4.2 (t, 1H, J = 7 Hz), 3.6 (m, 3H), 1.9 (m, 1H), 1.5 (m 2H) 1.0 (t, 3H), 13C-NMR (CDCI3) d156.0 144.0 142.0 127.6 127.0 124.9 119.9 66.5 65.0 54.7.47.3 24.3 10.4.
N-Fmoc-3-amino-1-propanol. Procedure as above starting from 3-amino- 1-propanol. White solid (95%). Mp 115-118°C. 1H-NMR (CDCl3) d 7.8 (d, 2H, J=6.5 Hz), 7.6 (d, 2H, J=6.5 Hz), 7.4
(m, 4H), 5.1 (m, 1H), 4.5 (d, 2H, J=7 Hz), 4.2 (t, 1H, J=7 Hz), 3.7 (m, 2H), 3.4 (q, 2H), 2.6 (m, 1H), 1.7 (p, 2H). 13C-NMR (CDCI3) d 142 136 128 127 125 120 67 60 48 38 33 trαnβ-N-Fmoc-4-amino-cyclohexanol. Procedure as above starting from trans-4-amino-cyclohexanol. White solid (37%) Mp 208-210°C. 1H-NMR (DMSO-d6) d 7.9 (d, 2H), 7.7 (d, 2H), 7..4 (m, 4H), 4.3 (m, 3H), 3.9 (m, 6H), 3.3 (s, 1H), 1.7 (m, 2H), 1.2 (m, 2H). 13C-NMR (DMSO-d6) d 155.3 143.9 140.7 127.6 127.0 125.2 120.0 68.1 65.1 49.2 46.8 34.0.30.5
Example 2
Procedure for the synthesis of aromatic dicarboxylic acid
(a) Methylation of phenolic alcohol 2-Nitro-5-methyl-anisole. To a suspension of 4.6 g (30 mmol) 2-nitro-5-methyl-phenol and 20 7 g (150 mmol) dry K2CO3 in 150 ml acetone was added 42 6 g (300 mmol) Mel. The reaction mixture was stirred at reflux 16 h, then cooled, filtered and concentrated in vacua. The residue was redissolved in EtOAc filtered and concentrated in vacuo to afford light yellow solid 4.9 g
(98%). Mp 56-57°C. 1H NMR (CDCl3) d 7.8 (d, 1H, J = 8.4 Hz), 6.9 (s, 1H), 6.8 (d 111 J = 8.4 Hz) 4.0 (s, 3H), 2.4 (s, 3H). 13C NMR (CDCl3) d 153. 1 145.9 125.8 120.8 1 13.9 108.5 56.2 21.8.
2-Methyl-3-nitro-anisole. Procedure as above starting from 2-methyl-3-nitro-phenol. Yellow solid (91%). Mp 51-52°C. 1H NMR (CDCl3) d 7.3 (d, 1H, J = 8.0 Hz), 7.2 (t, 1H, J = 8.0 Hz), 7.0 (d 1H, J = 8.0 Hz), 3.9 (s, 3H), 2.3 (s, 3H). 13C NMR (CDCl3) d 158.2 150.8 132.1 126.5 115.4 113.6
55.9 11.2.
2-Nitro-3-methyl-anisole. Procedure as above starting from 2-nitro-3-methyl-phenol. Yellow solid (98%). Mp 46-48°C. 1H NMR (CDCl3) d 7.3 (t, 1H, J = 8.5 Hz), 6.9 (d, 1H, J = 8.5 Hz), 6.8 (d 1H, J = 8.5Hz), 3.9 (s, 3H), 2.3 (s, 3H). 13C NMR (CDCl3) d 150.6 130.7 130.5 122.4 110.0 109.8
56.1 16.7.
(b) Hydrogenation of the nitro group
2-methoxy-4-methyl-aniline. To a solution of 4.9 g (29.3 mmol) 2-nitro-5-methyl-anisole in 100 ml EtOH and 5 ml cone. HCl under an N2 atmosphere was added 250 mg 5% Pd on charcoal. The solution was hydrogenated at 200 psi and room temperature. After 16 h the reaction mixture was filtered through Celite and concentrated in vacuo. The residue was chromatographed in hexane-/EtOAc 1: 1 to afford red oil 2.8 g (70%).1H NMR (CDCl3) d 6.7 (m, 3H), 3.9 (s, 3H), 3.7 (s, 2H), 2.4 (s, 3H). 13C NMR (CDCl3) d 147.0 133.2 127.7 120.9 114.8 111.1 55.1 20.7.
2-methyl-3-methoxy-aniline. Procedure as above starting from 3-nitro-2-methyl-anisole. Red oil (60%).1H NMR (CDCl3) d 7.1 (t, 1H, J = 8.0 Hz), 6.5 (dd 2H, J = 8.0 Hz) 3.9 (s, 3H), 3.8 (s 2H), 2.2 (s, 2H). 13C NMR (CDCl3) d 157.8 145.4 126.2 109.9 108.1 100.7 55.1 8.5.
(c) Diazotation of an amino group to a nitrile group (Sandmeier).
2-methyl-3-methoxy-benzonitrile. A solution of 2.5 g (18 mmol) 2-methyl-3-methoxy-aniline in 55 ml 2N HCl was cooled to -5°C in a ice/salt bath and stirred for 30 min. A solution of 1.37 g (19.8 mmol) NaNO2 In 28 ml H2O was added dropwise at -5°C. The reaction mixture was stirred 30 min and neutralised carefully with approximately 3.7 g Na2CO3, then a solution of 1.8 g (19.8 mmol) CuCN and 1.9 g (39.6 mmol) NaCN in 28 ml H2O was added in one portion. After 18 h the reaction mixture was extracted with 3*100 ml CHCl3. The combined organic phases was extracted with H2O, dried with Na2SO4 and concentrated in vacuo to afford dark red oil 2.0 g (75%). IR-data 2222 cm-1 (CN). 1H NMR (CDCl3) d 7.2 (q, 1H, J = 7.7 Hz), 7.15 (dd, 1H, J = 7.7 Hz, J = 1.5 Hz), 7.0 (dd, 1H, J = 7.7 Hz, J = 1.5 Hz), 3..9 (s, 3H), 2.4 (s, 3H). 13C NMR (CDCl3) d 157.5 130.8 127.1 123.7 117.9 113..9 113.5 55.4 14.1.
(d) Synthesis of benzophenone.
3,3'-dimethyl-benzophenone. To 3.6 g (110 mmol) Mg-turmngs under 10 ml THF was added a Iodine Crystal and ¼ of 17.1 g (100 mmol) 3-bromotoluene. The mixture was heated to 40°C and after a while the Gngnard reaction started. The rest (3/4) of the 3-bromotoluene in THF was added in such a rate to maintain reflux. After addition the reaction mixture was reflux for 1 h cooled to room temperature and added dropwise to a solution of 7.3 g (63 mmol) 3-methyl-benzonitrile in 40 ml toluene at room temperature, then kept at 70°C for 16 h. The reaction mixture was cooled on an ice bath and 33 ml cone. HCl was added dropwise followed by 170 ml MeOH and refluxed 7 h. The reaction mixture was cooled, 100 ml H2O was added and extracted with EtOAc. The combined organic phases was dried with MgSO4, filtered and concentrated in vacuo. The residue was chromatographed (hexane/EtOAc 19:1) to afford colourless oil 10.5 g (80%). 1H NMR (CDCl3) d 7.6 (m, 2H), 7.3 (m, 2H), 2.4 (s, 3H). 13C NMR (CDCl3) d 196.7 137.8 137.5 132.8 130.1 127.7 127.0 21.0.
2,4'-dimethyl-benzophenone. Procedure as above starting from 2-bromotoluene and 4-methylbenzonitrile. Colourless oil (77%). 1H NMR (CDCl3) d 7.7 (d, 2H, J = 8.2 Hz), 7.4-7.2 (m, 6H), 2.4 (s, 3H), 2.3 (s, 3H). 13C NMR (CDCl3) d 198.0 143.8 138.7 136.2 134.9 130.7 130. 1 129.8 129.0 128.0 124.9.
2-methoxy-2',5-dimethyl-benzophenone. Procedure as above starting from 2-bromo-4-methyl-anisole and 2-methyl-benzonitrile. THF used instead of toluene Colourless oil (36%). 1H NMR (CDCl3) d 7.4-7.1 (m, 6H), 6.8 (d, 1H, J = 8.0), 3.6 (s, 3H), 2.5 (s, 3H), 2.3 (s, 3H). 13C NMR (CDCl3) d 198.3 156.0 139.2 137.7 133.0 130.9 130.6 130.0 129.5 129.0 126.0 124.9 11 1.7 55.6 20.5 20.1.
2-methoxy-4',5-dimethyl-benzophenone. Procedure as above starting from 2-bromo-4¬methyl-anisole and 4-methyl-benzonitrile. Chromatographed in (hexane/EtOAc 9:1). colourless oil (56%). 1H NMR (CDCl3) d 7.7 (m, 2H), 7.3-7.1 (m, 4H), 6.9 (d, 1H, J = 8.4 Hz), 3.7 (s, 3H), 2.4 (s, 3H), 2.3 (s, 3H). 13C NMR (CDCl3) d 196.8 155.0 143.6 135.1 131.9 129.9 129.6 128.8 111.3 108.7 55.6 21.6 20.2.
(e) Synthesis of benzophenone via benzhydrole.
4,4'-dimethyl-benzhydrole.. To 3.6 g (150 mmol) Mg-turnings under 10 ml THF was added a Iodine Crystal and ¼ of 17.1 g (100 mmol) 4-bromotoluene. The mixture was heated to 40°C and after a while the Grignard reaction started. The rest (3/4) of the 4-bromotoluene in THF was
added in such a rate to maintain reflux. After addition the reaction mixture was reflux for 1 h, cooled to 0°C and the remaining Mg-turmngs was removed. A solution of 12.3 g (103 mmol) 4-methyl-benzaldehyde in 20 ml THF at 0°C was dropwise added. After 2 h the reaction mixture was quenched with 200 ml ice, temperature allowed to rise to room temperature and 25% H2SO4 was added until solution was clear. The reaction mixture was extracted with DCM. The combined organic phases was dried with MgSO4, filtered and concentrated in vacuo. The residue was recrystahsed in heptane to afford white solid 10.6 g (50%) Mp 64-65°C. 1H NMR (CDCI3) d 7.2 (d 4H, J = 8.1 Hz), 7.1 (d, 4 H, J = 8.1 Hz), 5.8 (s, 1 H), 2.3 (s, 6H). 13C NMR (CDCl3) d 141.1 137.1 129.1 126.4 77.5 21.1.
4,4'-dimethyl-benzophenone. To a suspension of 12 96 g (60 mmol) pyridinium chloro chromate In 60 ml DCM was added 6.36 g (30 mmol) 4,4'-dimethyl-benzhydrole. The mixture was stirred 24 h and 240 ml diethylether was added. The reaction mixture was filtered 3X through silica gel and concentrated in vacuo to afford white solid 3.7 g (59%) Mp 92-94°C. 1H NMR (CDCl3) d 7 7 (d, 4H, J = 7.9 Hz), 7.3 (d, 4H, J = 7.9 Hz), 2.4 (s, 6H). 13C NMR (CDCl3) d 196.2 142.8 135 1 130.1 128.8 21.5.
(f) Procedure for the Synthesis of methyl-methylphenyl-benzene 2-methyl-(4-methylphenyl)-benzene. To a solution of 5.2 g (24 mmol) 2-Iodotoluene in 12 ml diethylether under an atmosphere of N2 at -78°C was dropwise added 32 ml 1.5 M (48 mmol) tert-BuLi in hexane. The reaction mixture was stirred 1 h at -78°C and 1 h at room temperature followed by concentration in vacuo. To the residue was added 16 ml THF at 0°C and the reaction mixture was dropwise added to a solution of 3.3 g (24 mmol) dry ZnCl2 in 12 ml THF under an atmosphere of N2 at 0°C. The reaction mixture was stirred 1 h at room temperature, then added to a solution of 3.4 g (20 mmol) 4-bromo-toluene. 0.23 g (0.2 mmol) Pd(PPh3)4 in 20 ml THF under an atmosphere of N2 cooled in a water bath. The reaction mixture was stirred 16 h at 50°C cooled and poured in a solution of 20 ml diethylether and 60 ml 4N HCl. The mixture was extracted with 2*40 ml ether. The combined organic phases was washed with NaHCO3 (sat.), dried with MgSO4 and concentrated in vacuo to afford colourless oil 2.0 g (47%). 1H NMR (CDCI3) d 7.2 (m, 8H), 2.3 (s, 3H), 2.2 (s, 3H).
(g) Aromatic Side Chain Oxidation of methyl-groups Biphenyl-2,4'-dicarboxylic acid. To a solution of 5.2 g (33 mmol) KMnO4 in 48 ml 50% pyridine (aq. ) at 100°C was added 0.6 ml cone. NaOH and a solution of 2.0 g (1 1 mmol) 2-methyl-(4-methylphenyl)-benzene in 15 ml pyridine followed by 15 ml H2O. The reaction mixture was stirred 1 h and 5.2 g (33 mmol) KMnO4 was added. This procedure was continued to a total of 41.6 g (264 mmol) KMnO4 was added. The hot reaction mixture was filtered and the filter cake
was washed with 4*30 ml H2O and 10 ml pyridine. The filtrate was cooled in a ice bath and acidified to pH = 1 with cone. HCl Brine was added and the reaction mixture was extracted with 4* 150 ml EtOAc. The combined organic phases was concentrated in vacuo to afford white solid 0.9 g (33%). Mp 270°C.1H NMR (DMSO-d6) d 10.9 (broad, 2H), 8.0 (d, 2H, J = 8.0 Hz), 7.8 (d, 1H J = 8.0 Hz), 7.6 (t, 1H, J = 8.0 Hz), 7.5 (t, 1H, J = 8.0 Hz) 7.45 (d, 211, J = 8.0 Hz), 7.4 (d, 111, J = 8.0 Hz). 13C NMR (DMSO-d6) d 169.3 167.3 145.5 140.4 132.1 131.2 130..5 129.5 129. 1 128.6 128.6 127.9.
Benzophenone-2,2'-dicarboxylic acid. Procedure as above starting from 2,2'-dimethylbenzophenone. White solid (69%) . Mp 208-210°C, 1H NMR (DMSO-d6) d 8.7 (broad, 2H), 7.8 (d, 2H, J = 6.6 Hz), 7.6 (m, 4H), 7,4 (d, 2H, J = 6,6 Hz). 13C NMR (DMSO-d6) d 168.6 138.6 132.8 131.1 130..8 129.3 128.9.
Benzophenone-3,3'-dicarboxylic acid. Procedure as above starting from 3,3 -dimethylbenzophenone. White solid (56%). Mp 330°C (decomp. ). 1H NMR (DMSO-d6) d 8.25 (s, 2H), 8.25 (m, 1H), 8.1-7.85 (m, 3H), 7.7 (m, 2H). 13C NMR (DMSO-d6) d 194.8 166.6 137.0 133.8 133.4 131.2 130.2 129.3.
Benzophenone-4,4'-dicarboxylic acid. Procedure as above starting from 4,4 -dimethylbenzophenone. White solid (66%). Mp 355°C (decomp.). 1 H NMR (DMSO-d6) d 8.1 (d 4H, J = 8.0 Hz), 7.8 (d, 4H, J = 8.0 Hz). 13C NMR (DMSO-d6) d 195.0 166.6 140.0 134.3 129.8 129.5.
Benzophenone-2,4'-dicarboxylic acid. Procedure as above starting from 2,4'-dimethylbenzophenone. White solid (72%). Mp 241-243°C.
1H NMR (DMSO-d6) d 8.0 (m, 3H), 7.7 (m, 4H), 7.5 (d, 1H, J = 7.6 Hz). 13C NMR (DMSO-d6) d 166.9 166.7 141.5 140.5 134.5 132.7 130.1 129.6 129.6 128.9 127.5 127.5.
2-Methoxy-benzophenone-2',5-dicarboxylic acid. Procedure as above starting from 2-methoxy-2,5'-dimethyl-benzophenone. White solid (64%). Mp 224-227°C. 1H NMR (DMSO-d6) d 8.2-8.0 (m, 2H), 7.9-7.8 (m, 1H), 7.7-7.5 (m, 2H), 7.3 (m, 1H), 7.2 (m, 1H), 3.6 (s, 3H) . 13C NMR (DMSO-d6) d 195.0 167.5 166.5 143.5 135.2 132.9 132.4 130.8 129.6 129.1 126.3 122.6 112.9 56.1.
Example 3 Procedure for the synthesis of mono-allylated aromatic diacids
Benzophenone-2,2'-dicarboxylic acid monoallyl ester. To a solution of 1.08 g (4 mmol) Benzophenone-2,2'-dicarboxylic acid In 90 ml DMF was added 0.16 g (0.5 mmol) Cs2CO3. After 30
min. 0.34 ml (0,484 g, 4 mmol) allyl bromide. The reaction mixture was stirred 24 h and 0.16 g (0.5 mmol) Cs2CO3 was added. This procedure was continued until a total of 0.64 g (2 mmol) Cs2CO3 was added. After additional 24 h the reaction mixture was filtered and chromatographed (CHCl3/AcOH 99: 1) to afford 0.52 g (42%) Mp 205-207°C. Unreacted benzophenone-2,2'-dicarboxylic acid 0.312 g (29%) was isolated for reuse. 1H NMR (CDCl3) d 8.8 (broad, 1H), 8.0-7.3 (m, 8H), 6.0-5.7 (m, 1H), 5.3-5.1 (m, 2H), 4.7 (d, 2H, J = 7.0). 13C NMR (CDCl3) d 171.0 167.4 139.3 138.8 135.0 131.9 131.4 131.4 131.1 130.2 129.7 129.3 129.2 128.0 125.9 118.7 66.4.
Benzophenone-3,3'-dicarboxylic acid monoallyl ester. Procedure as above starting from benzophenone-3,3'-dicarboxylic acid. White solid (42%) Mp 140- 143°C. 1H NMR (CDCl3) d 8.5 (m, 2H), 8.4-8.3 (m, 2H), 8.1-7.8 (m, 2H), 7.7-7.5 (m, 2H), 6.1-5.9 (m, 1H), 5.5-5.2 (m, 2H), 4.9 (d, 2H, J = 7.0 Hz). 13C NMR (CDCl3) d 194.6 170.6 165.3 137.5 137.3 134.8 134.0 133.6 131.8 131.5 130.9 130.6 130.2 129.8 129.7 128.9 128.8 118.6 65.9. Benzophenone-4,4'-dicarboxylic acid monoallyl ester. Procedure as above starting from benzophenone-4,4'-dicarboxylic acid. White solid (5%). Mp 263°C (decomp.).1H NMR (DMSO-d6) d 11.7 (broad, 1H), 8.2 (m, 4H), 7.9 (m, 4H), 6.2-6.0 (m, 1H), 5.5-5.3 (m. 2H), 4.9 (d, 211, J = 7.0 Hz). Benzophenone-2,4'-dicarboxylic acid monoallyl ester. Procedure as above starting from benzophenone-2,4'-dicarboxylic acid. White solid (64%) of the 2 isomers in ratio 7:1 (2-allylester/4'-allylester). Chromatographed (CHCl3/ MeOH/ triethylamine 8:1 :1) to afford pure white solid of 2-allylester (39%) (Mp 125-127°C) and pure white solid of 4'-allylester (6%) (mp 119-120°C) 2-allylester: 1H NMR (CDCl3) d 10.8 (broad, 1H), 8.2-8.1 (m, 3H), 7.8 (d 2H, J = 8.4 Hz), 7.4 (dd, 1H, J = 7.4 Hz, J = 1.6 Hz), 5.7 (m, 1H), 5.2 (m, 2H), 4.5 (d, J = 7.0 Hz). 13C NMR (CDCl3) d 196.2 170.8 165.3 141.0 140.9 132.8 132.6 131.2 131.0 130.8 130.2 129.9 129.0 128.9 127.6 125.2 118.7 66.1. 4'-allylester: 1H NMR (CDCl3) d 9.2 (broad, 1H), 8.1 (d, 3H, J = 8.2 Hz), 7.75 (d, 2H, J = 8.2 Hz), 7.7 (dt, 1H, J = 7.5 Hz, J = 1.2 Hz), 7.6 (dt, 1H, J = 7.5 Hz, J = 1.2 Hz), 7.4 (d, 1H, J = 7.5 Hz), 6.1-5.9 (m, 1H), 5.5-5.3 (m, 2H), 4.8 (d, J = 7.0 Hz). 13C NMR (CDCl3) d 196.3 170.1 165.3 141.9 140.2 133.7 133.3 131.7 130.8 129.8 129.8 129 6 129.0 127.8 127.5 127.4 118.5 65.9.
Biphenyl-2,2'-dicarboxylic acid monoallyl ester. Procedure as above starting from biphenyl-2,2'-dicarboxylic acid. Colourless oil (35%). Biphenyl-2,2'-dicarboxylic acid (40%) was isolated for reuse. 1H NMR (CDCl3) d 8.0 (m, 2H), 7.6-7.4 (m, 4H). 7.2 (d, 2H, J = 7.2 Hz), 5.7-5.6 (m, 1H), 5.2-5.0 (m, 2H), 4.5 (d, 2H, J = 5.9 Hz). 13C NMR (CDCl3) d 171.5 166.7 143.7 142.8 134.0 132.0 131.7 131.4 130.5 130.3 130.1 129.9 129.2 128.4 127.2 118.0 65.4.
Naphthoic-2,6-dicarboxylic acid monoallyl ester. Cs2CO3 (1.60g, 5.00 mmol) was added in two equal portions over 0.5 h to a solution of naphthoic-2 6-dicarboxylic acid (2.16g, 10.0 mmol) in anhydrous DMF (97 mL). Allyl bromide (17.3 mL, 200 mmol) was then added and the reaction mixture stirred vigorously for 24 h. The same amount of Cs2CO3 was then added in two equal portions over 8 h and the reaction allowed to proceed for a further 17 h. The precipitate was filtered and rinsed with DMF (3 × 20 mL). The combined filtrate was then concentrated in vacuo and extracted with hot 50% MeOH/acetone (2 × 100 mL) . After evaporation of the solvent, residual starting material was removed by silica gel chromatography (acetone/hexane/HOAc, 50/48/2). The resulting fractions which contained a mixture of the monoester and the diester was concentrated, redissolved in 10 % MeOH/dichloromenthane, and treated with Amberlyst A-26 (hydroxide form) resin (24.0 g, 96 meq) for 17 h. The resin was then filtered and washed with fresh solvent (about 3 L) until no diester was detected in the effluent by TLC (CHCla/MeOH, HOAc, 94/4/2). The monoallyl ester was then eluted with MeOH/dichloromethane/acetic acid (10:80:10). After solvent removal, recrystalhsation from acetone gave 3 as a fine colourless solid (0.77 g, 30 %), Mp 217-218°C. δ (250 MHz, DMSO-d6): 4.88 (d, 2H, CH2-CH=CH2, J = 5.1 Hz), 5.30 (m, 1 H, CH2-CH=CH2), 5.45 (m, 1 H, CH2-CH=CH2), 6.10 (m, 1H CH2-CH=CH2), 8.05 (m, 2H, H4 and H8), 8.25 (d, 2H, H 1 and H3, J=8.4 Hz), 8.70 (dd, 2H, H5 and H7, J=15.5, 3.9 Hz) Elemental analysis (C15H12O4): C: 69.77% (calcd.70.3%): H: 4.51% (calcd. 4.72%). EIMS calculated for C15H12O4 256, found 256.
Example 4
Solid Phase Synthesis of Balanol Analogues The balanol libraries was synthesised using split-synthesis-method. After each step the resins was mixed and swollen in a isopycnic mixture of 1,2-dichlorethane and DMF (2:1) and the resin was split for the next step in the synthesis. To analyse the contents attached to the resin, it was cleaved of the resin using a solution of 50% TFA in dichloromethane. Two dicarboxylic acids were used in step (A) (m=2), four aminoalcohols were used in step (B) (n=4), and four aromatic carboxylic acid were used in step (C) (o=4). Thus a library having 2*4*4=32 compounds was prepared.
(A) Coupling of aromatic acids to a Wang resin
(corresponding to step (A) in the general scheme)
Phthalic acid and naphthalene-2,6-dicarboxylic acid as the internal anhydride and the monoallyl esters, respectively, were coupled to a Wang resin using 2 different methods.
Coupling of phthalic acid to a Wang Resin. 1.6 g (0.87 meq/g) Wang resin (polystyrene cross-linked with 1% divinylbenzene from NovaBiochem) was swollen in 10 ml dry DMF and 2.83 g (1.6 mmol) phthalic-anhydride, 1.95 ml (1.425 g (14.1 mmol) EtsN and 0.2346 g ( 1.92 mmol) DMAP was added. The reaction mixture was shaken for 4 days, then washed with 2*10 ml 30% MeOH in dichloromethane and 4*10 ml dichloromethane. The resm was dried and analysed on HPLC Loading L = 0 66 meq/g.
Coupling of naphthalene-2,6-dicarboxylic acid monoallyl ester on Wang resin. 0.8 g ( 0.87 meq/g) Wang resin was swollen in 8 ml dry DMF and 0.321 g (1.25 mmol) naphthalene-2,6-dicarboxylic acid monoallyl ester, 0.412 g (1.39 mmol) MSNT and 0.443 ml (5.57 mmol) 1 -methyllmidazole (NMI) was added. The reaction mixture was shaken 4 days and washed with 2*10 ml 30% MeOH in dichloromethane and 4*10 ml dichloromethane. The resin was dried and analysed on HPLC. Loading L = 0.87 meq/g.
Deallylation of the immobilised naphthalene-2,6-dicarboxylic acid allyl ester. To a 5% HOAc and 2,5% NMM solution in 15 ml CHCl3 was added 2,4 g (2.09 mmol) Pd(PPhs)4 under Argon. The mixture was shaken 10 mm and 0.8 g ( 0.87 meq/g, 0.696 mmol) mono-allylated resin was added under Argon. The reaction mixture was shaken 18 h and washed with 6*15 ml 0.5% DIPEA, 0.5 sodium-diethyl-dithio-carbamate in DMF for each 10 min and 3*15 ml
dichloromethane. The resin was dried and analysed on HPLC Loading L = 0.83 meq/g.
Coupling of N-Fmoc-aminoalcohols on -COOH functionalised resin
(corresponding to step (B))
Four different N-Fmoc-aminoalcohols were used. trans-N-Fmoc-4-amino-1-cyclohexanol. 0.4 g (0.87-0.66 meq/g) -COOH functionalised resin was swollen in 5 ml dry dichloromethane and a solution of 0.27 g (0.8 mmol) trans-N-Fmoc-4-amino- 1-cyclohexanol in 5 ml dry dichloromethane was added. The reaction mixture was shaken 2 min and 0.237 g (0.8 mmol) MSNT and 0.254 ml (3.2 mmol) NMI was added. After 4 days the reaction mixture was washed with 10 ml dichloromethane, 10 ml of 30% MeOH in DCM, 10 ml DMF and 2*10 ml DCM. The resin was dried and analysed on HPLC to identify the two products.
N-Fmoc-1-amino-2-propanol. Procedure as above using 0.238 g (0.8 mmol) N-Fmoc-1-amino-2-propanol The two products was identified on HPLC.
N-Fmoc-2-amino-1-butanol. Procedure as above using 0.249 g (0.8 mmol) N-Fmoc-2-amino-1-butanol. The two products was identified on HPLC.
N-Fmoc-3-amino-1-propanol. Procedure as above using 0.238 g (0.8 mmol) N-Fmoc-3-amino-1-propanol. The two products was identified on HPLC.
Coupling of benzoic acid derivatives on -NH2 functionalised resin
(corresponding to step (C)) Four different benzoic acids was used.
Diisopropylethylammonium salt of 4,4'-Dimethoxytrityl-oxymethyl-benzoic acid.0.4 g (approx 0.6 meq/g) -NH-Fmoc functionalised resin was washed with 2*10 ml 20% piperidine in DMF 2*40 mm and 3*10 ml DMF. The resin was swollen in 7 ml dry DMF and 0.584 g (1.0 mmol) diisopropylethylaminonium salt of 4,4'-Dimethoxytrityl-oxymethyl-benzoic acid was added followed by addition of 0.520 g (1.0 mmol) PyBOP, 0.135 g (1.0 mmol) HOBT and 0.33 ml (2.0 mmol) DIPEA. After 4 days the resin was washed with 2*10 ml DMF, 2*10 ml 30% MeOH in DCM and 2*10 ml DCM for each 10 min. 4-nitro-benzoic acid. 0.4 g (approx.0.6 meq/g) -NH-Fmoc functionalised resin was washed with 2*10 ml 20% pipendine in DMF 2*40 mm and 3*10 ml DMF. The resin was swollen in 7 ml dry DMF and 0.167 g (1.0 mmol) 4-nitrobenzoic acid was added followed by addition of 0.520 g (1 0 mmol) PyBOP, 0.135 g (1.0 mmol) HOBT and 0.33 ml (2.0 mmol) DIPEA. After 4 days the resm was washed with 2*10 ml DMF, 2*10 ml 30% MeOH in DCM and 2*10 ml DCM for each 10 min.
4-methoxy-benzoic acid. Procedure as above using 0.152 g (1.0 mmol) 4-methoxy-benzoic acid.
3-fluoro-benzoic acid. Procedure as above using 0.140 g (1.0 mmol) 3-fluoro-benzoic acid.
Cleavage of the combinatorial library from the Wang resin
(corresponding to step (D))
In order to implement this synthesis on solid-phase, the outcome and optimisation of the key coupling reactions were followed by a cleave-&-analyse technique. Following this cleave-&-analyse technique, approximately 5 mg resin was weighted on an analytical balance and cleaved by trifluoroacetic acid (TFA)/dichloromethane (DCM) (1:1, v/v), evaporated (Speed- Vac™), redissolved and quantified by reverse-phase HPLC pre-cahbrated using minimum three
standard concentrations. The products were cleaved by TFA/DCM (1:1 , v/v) when a W ang-typp resin was applied for the synthesis of the combinatorial library and analysed using diode-array HPLC-UV (Hitachi) and HPLC-MS (Perkm-Elmer, Sciex) to identify the constituents of each of the four sub-libraries
The 4,4'-Dimethoxytrityl-oxymethyl-benzoic acid batch. The DMT protecting group was removed by washing with 4*10 ml 3% dichloroacetic acid in DCM followed by wash with 4*10 ml DCM. The resin was dried and analysed on HPLC (LC-MS) and 6 of the 8 theoretically obtainable balanol analogues were identified.
The 4-nitro-benzoic acid batch. The resin was dried and analysed on HPLC (LC-MS) and 7 of the 8 theoretically obtainable balanol analogues were identified.
The 4-methoxy-benzoic acid batch. The resin was dried and analysed on HPLC (LC-MS) and 7 of the 8 theoretically obtainable balanol analogues were identified.
The 3-fluoro-benzoic acid batch. The resin was dried and analysed on HPLC (LC-MS) and 7 of 8 theoretically obtainable balanol analogues. In the sub-libraries above, i. e. the 4,4'-Dimethoxytrityl-oxymethyl-benzoic acid batch, the 4-nitrobenzoic acid batch, the 4-methoxy-benzoic acid batch, and the 3-fluoro-benzoic acid batch, 6 7, 7, and 7 balanol-structures, respectively, were identified as distinct peaks in the LC-UV/MS analyses. The remaining five balanol analogues containing either one of the isomeric building blocks 1-amino-propan-2-ol or 3-amino-propan- 1-ol were not observed In the analysis of the library. Several reasons can be proposed to account for this observation where precipitation of individual library members or co-elution in HPLC are very likely possibilities.
Claims
1. A method for the preparation of a compound of the following general formula I: K-C(=O)-A-C(=O)-L1-B-L2-C(=O)-D
wherein
K·C(=O)- designates a carboxy group or a derivative thereof; each of A and B designates an organic biradical; each of L1 and L2 independently designates -NR5- or -O-, wherein each R5 independently is selected from hydrogen, optionally substituted C1-20-alkyl, optionally substituted C1-20- alkenyl, optionally substituted C1-20-alkadienyl, optionally substituted C1 -20-alkatrienyl, optionally substituted aryl, and optionally substituted heteroaryl, or R3 designates an additional bond to B (whereby B becomes a triradical);
D designates optionally substituted aryl or optionally substituted heteroaryl; comprising the following steps
(A) providing an optionally functional group protected moiety -C(=O)-A-C(=O)-M1 immobilised to a solid support material, wherein -C(=O)-M1 designates a carboxy group or a derivative thereof, (B) coupling an optionally functional group protected difunctional entity L'1-B-L'2 to the
-C(=O)-M1 end of the immobilised moiety -C(=O)-A-C(=O)-M1 for the formation of an optionally functional group protected immobilised fragment -C(=O)-A-C(=O)-L1-B-L'2,
(C) couphng an optionally functional group protected entity D-C(=O)-M2, wherein C(=O)- M2 designates a carboxy group or a derivative thereof, to the L'2 end of the immobilised fragment -C(=O)-A-C(=O)-L1-B-L'2 for the formation of an optionally functional group protected immobilised compound -C(=O)-A-C(=O)-L1-B-L2-C(=O)-D the step optionally including deprotection of any protection group involved in L'2, and (D) cleaving the compound K-C(=O)-A-C(=O)-L1-B-L2-C(=O)-D from the solid support material, the step optionally including deprotection of one or more functional group(s) attached to A, B, and/or D
2. A method according to claim 1, w herein the organic biradical -C(=O)-A-C(=O)- is an aliphatic biradical of the formula
-C(=O)-(CR3R4)n-C(=O)- wherein n is 1-20, preferably 1- 12, in particular 2-8, and where each of R3 and R4 independently is selected from hydrogen, optionally substituted C1 -6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C4-8-alkadienyl, optionally substituted C6-8-alkatrienyl, hydroxy, oxo (thereby forming a keto or aldehyde functionality), -O-R6, formyl, -C(=O)-R6, -O-C(=O)-R6, carboxy, -C(=O)-O-R6, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted aryl, optionally substituted aryloxy, halogen such as fluoro, chloro, bromo, and lodo nitro, cyano, -N(R5)2, -N(R7)-CO-R6, carbamoyl, mono- or di(C1 -6-aIkyl)aminocarbonyl, sulphanyl, optionally substituted C1-6-alkylthio, optionally substituted C1-6-alkylthio-C1-6-alkyl, (optionally substituted aryl)thio, guanidino, sulphono
(-SO3H), sulphino (-SO2H), halosulphonyl, -OS(O)m-R6 where m is 2 or 3, -N(R7)S(O)m-R6 wherein is 2 or 3, -S(O)m=N(R7)2 where m is 2 or 3, -S(O)m-NH(R7) where m is 2 or 3, -S(O)m-NH2 wherein is 2 or 3, isocyano, isothiocyano, thiocyano, -OP(O)P(R6)q where p is 1, 2, or 3, q is 1 or 2, and p+q is 3, 4, or 5, and -N( R7)P(O)p(R6) q where p is 1, 2, or 3, q is 1 or 2, and p+q is 3,
4, or 5, wherein each R5 and each R6 independently is selected from hydrogen, optionally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-aIkadienyl, optionally substituted C6-20-alkatrienyl, optionally substituted aryl, and optionally substituted heteroaryl, and each R7 is selected from hydrogen and C1-4-alkyl, where at the most 5, preferably at the most 3, of the substituents R3 and R4 are different from hydrogen, or a biradical as illustrated in Figure 1 and 2, wherein X is selected from the group consisting of >NR5, >NH, -O-, -S-, -Se-, -Te-, -CR1R2-, >C=O, >C=S, and Y1, Y2, R1, and R2 each independently designate substituents as defined as optional substituent for aryl and heteroaryl (see above), or Y1 together with Y2 may form a biradical which together with the atoms located between these substituents, form(s) a 4-, 5-, 6-, 7- or 8-membered ring which may be an optionally substituted non-aromatic carbocyclic or heteroaromatic ring or an optionally substituted aromatic or heteroaromatic rings, and each Z1 and Z2 independently designates =N-, =N+R5- 3. A method according to claim 1 or 2, wherein the organic biradical -L1-B-L2- is an aliphatic biradical of the formula
-L1-(CR3R4)n-L2- where L1, L2, R3, R4 and n are as defined in claims 1 and 2, or
an aliphatic or aromatic amino alcohol as illustrated in Figure 3, wherein X is selected from the group consisting of >NR6, >NH, -O-, -S-, -Se-, -Te-, -CR1R2-, >C=O, >C=S, and Y1 Y2 R1, and R2 each independently designates optional substituents, or Y1 together with Y2 may form a biradical which together with the atoms located between these substituents, form(s) a 4-, 5-, 6-, 7- or 8-membered ring which may be an optionally substituted non-aromatic carbocyclic or
heteroaromatic ring or an optionally substituted aromatic or heteroaromatic rings, and each Z1 and Z2 independently designates =N-, =N+R5-. 4. A method according to any of the preceding claims wherein one of L1 and L2 designates -O- and the other designates -NR5-, wherein RB designates hydrogen, C1-44alkyl or an additional bond to B.
5. A method according to any of the preceding claims, wherein K designates OH, O- OR", NH2 NHR, or NRR', in particular OH, methoxy, or NH2, where R and R' are selected from C1 -6-alkyl and benzyl, and R" is selected from C1-6-alkyl, C2-6-alkenyl, phenyl, and benzyl.
6. A method according to any of the preceding claims, further comprising a step (E) performed after the step (D), where the step (E) comprises conversion of one compound of the general formula 1 to another compound of the general formula I.
7. A method for the preparation of a multi-dimensional array of compounds, {A}-{B}-{D} consisting of at least four compounds each having the general formula I K-C(=O)-A-C(=O)-L1-B-L2-C(=O)-D I wherein
K-C(=O)- designates a carboxy group or a derivative thereof, each of A and B designates an organic biradical, each of L1 and L2 independently designates -NR5- or -O-, wherein each R5 independently is selected from hydrogen, optionally substituted C1-20-alkyl, optionally substituted C1-20- alkenyl, optionally substituted C1-20-alkadienyl, optionally substituted C1-20-alkatrienyl, optionally substituted aryl, and optionally substituted heteroaryl, or R3 designates an additional bond to B (whereby B becomes a triradical);
D designates optionally substituted aryl or optionally substituted heteroaryl;
comprising
(A) providing an array {A} of m optionally functional group protected moieties -C(=O)-A- C(=O)-M1 immobilised to a solid support material, wherein -C(=O)-M1 designates a carboxy group or a derivative thereof; (B) couphng an array {B} of n optionally functional group protected difunctional entities
L'1-B-L'2 to the -C(=O)-M1 end of the immobilised moieties -C(=O)-A-C(=O)-M1 for the formation of an array {A}-{B} of m*n optionally functional group protected immobilised fragments -C(=O)-A-C(=O)-L1-B-L'2; (C) coupling an array {D} of o optionally functional group protected entities D-C(=O)-M2, wherein -C(=O)-M2 designates a carboxy group or a derivative thereof, to the L'2 end of the immobilised fragments -C(=O)-A-C(=O)-L1-B-L'2 for the formation of an array {A}-{B}-{D} of m*n*o optionally functional group protected immobilised compounds -C(=O)-A-C(=O)-L1-B- L2-C(=O)-D, the step optionally including deprotection of any protection group involved in L'2, and
(D) cleaving the array {A}-{B}-{D} of compounds K-C(=O)-A-C(=O)-L1-B-L2-C(=O)-D from the solid support material, the step optionally including deprotection of one or more functional group(s) attached to individual As, Bs, and/or Ds; with the proviso that m*n*o is at least 4, preferably in the range of 6-200, more preferably in the range of 6- 100, in particular in the range of 8-64.
8. A method according to claim 7. wherein the organic biradical -C(=O)-A-C(=O)- is as defined in claim 2.
9. A method according to claim 7 or 8, wherein the organic biradical -L1-B-L2- is as defined in claim 3.
10. A method according to any of the claims 7-9, wherein one of L1 and L2 designates -O- and the other designates -NR5-, wherein R5 designates hydrogen, C1-4-alkyl or an additional bond to B.
11. A method according to any of the claims 7-10, wherein K designates OH, O-, OR", NH2, NHR, or NRR', In particular OH, methoxy, or NH2, where R and R' are selected from C1-6-alkyl and benzyl, and R" is selected from C1-6-alkyl, C2-6-alkenyl, phenyl, and benzyl.
12. A method according to any of the claims 7- 1 1, further comprising a step (E) performed after the step (D), where the step (E) comprises conversion of at least some of the compounds in the array of compounds of the general formula I to other compounds of the general formula I.
13. The use of an array of compounds according to any of the claims 7- 13 for screening purposes.
14. The use of a compound prepared according to a methods defined in any of the claims 1-6 or 7¬
13 as a medicament.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK13696 | 1996-02-09 | ||
DK13696 | 1996-02-09 | ||
PCT/DK1997/000058 WO1997029091A1 (en) | 1996-02-09 | 1997-02-10 | Balanol analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0880503A1 true EP0880503A1 (en) | 1998-12-02 |
Family
ID=8090158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97901527A Withdrawn EP0880503A1 (en) | 1996-02-09 | 1997-02-10 | Balanol analogues |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0880503A1 (en) |
JP (1) | JP2000504672A (en) |
AU (1) | AU1540997A (en) |
WO (1) | WO1997029091A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7226799B2 (en) | 2002-09-06 | 2007-06-05 | E. I. Du Pont De Nemours And Company | Methods for producing full-color organic electroluminescent devices |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1418244A1 (en) * | 1997-12-19 | 2004-05-12 | Affymetrix, Inc. | Exploiting genomics in the search for new drugs |
WO1999032660A1 (en) * | 1997-12-19 | 1999-07-01 | Affymetrix | Exploiting genomics in the search for new drugs |
US20020010550A1 (en) | 1998-09-14 | 2002-01-24 | George M. Grass | Pharmacokinetic-based drug design tool and method |
WO2000042213A1 (en) * | 1999-01-13 | 2000-07-20 | The Research Foundation Of State University Of New York | A novel method for designing protein kinase inhibitors |
KR100371971B1 (en) * | 1999-09-30 | 2003-02-14 | 주식회사 펩트론 | A Chemical Library Preparation Method from Natural Product |
US20020146684A1 (en) * | 2001-04-09 | 2002-10-10 | Meldal Morten Peter | One dimensional unichemo protection (UCP) in organic synthesis |
US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2504192A (en) * | 1991-08-22 | 1993-03-16 | Sphinx Pharmaceuticals Corporation | Protein kinase c inhibition and novel compound balanol |
-
1997
- 1997-02-10 JP JP9528073A patent/JP2000504672A/en active Pending
- 1997-02-10 WO PCT/DK1997/000058 patent/WO1997029091A1/en not_active Application Discontinuation
- 1997-02-10 AU AU15409/97A patent/AU1540997A/en not_active Abandoned
- 1997-02-10 EP EP97901527A patent/EP0880503A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9729091A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7226799B2 (en) | 2002-09-06 | 2007-06-05 | E. I. Du Pont De Nemours And Company | Methods for producing full-color organic electroluminescent devices |
Also Published As
Publication number | Publication date |
---|---|
AU1540997A (en) | 1997-08-28 |
JP2000504672A (en) | 2000-04-18 |
WO1997029091A1 (en) | 1997-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU764464B2 (en) | Collections of compounds | |
JP4689826B2 (en) | Compound collection | |
EP0734398B1 (en) | Compounds and methods | |
Grehn et al. | Novel efficient total synthesis of antiviral antibiotic distamycin A | |
TenBrink | A method for the preparation of stereochemically defined. psi.[CH2O] pseudodipeptides | |
CA3046171A1 (en) | Multicyclic peptides and methods for their preparation | |
EP0880503A1 (en) | Balanol analogues | |
JP4012145B2 (en) | Solid phase synthesis of pyrrole-imidazole polyamide | |
Cristofaro et al. | Enantioselective and diastereoselective molecular recognition of cyclic dipeptides by a C2 macrolactam host | |
US5525734A (en) | Methods for synthesizing diverse collections of pyrrolidine compounds | |
Hermann et al. | Syntheses of hapalosin analogs by solid-phase assembly of acyclic precursors | |
WO1999003832A1 (en) | Piperidine oligomers and combinatorial libraries thereof | |
US6562944B1 (en) | Amide library formation using a “by-product-free” activation/coupling sequence | |
US20220315623A1 (en) | Cyclic Peptide Compound Simulating Natural Product Structure, And Method For Preparation Thereof | |
JP2000501068A (en) | Actinomycin D analog | |
US20100210474A1 (en) | Heterocyclic scaffolds useful for preparation of combinatorial libraries, libraries and methods for preparation thereof | |
US6737541B2 (en) | Preparation of nitrogen mustard derivatives | |
WO2007117053A1 (en) | New diaza-bridged heterocycle derivatives and solid-phase preparation method thereof | |
WO2002072582A1 (en) | Methods for the synthesis of densely functionalized pyrrolidine template libraries | |
KR20040027605A (en) | Tetrahydro-1,4-benzodiazepine-2-one derivatives as beta turn peptidomimetics and its solid phase synthetic method | |
JPS5888385A (en) | 7-oxa-2-azabicyclo(2,2,1)hept-2-ene derivative and its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980909 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20000215 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 20011008 |